Antimüllerian hormone serum levels: a putative mark

Fertility and Sterility 77, 357-362

DOI: 10.1016/s0015-0282(01)02993-4

Citation Report

#	Article	IF	CITATIONS
1	Fertility after cancer therapy. , 0, , 73-86.		0
2	Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Human Reproduction, 2002, 17, 3065-3071.	0.4	836
3	Insulin but not insulin-like growth factor-1 promotes the primordial to primary follicle transition. Molecular and Cellular Endocrinology, 2002, 192, 37-43.	1.6	142
4	Elevated Serum Level of Anti-Mullerian Hormone in Patients with Polycystic Ovary Syndrome: Relationship to the Ovarian Follicle Excess and to the Follicular Arrest. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5957-5962.	1.8	595
5	Value of elevated basal follicle-stimulating hormone levels and the differential diagnosis during the diagnostic subfertility work-up. Fertility and Sterility, 2003, 79, 489-490.	0.5	29
6	Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation. Human Reproduction, 2003, 18, 328-332.	0.4	184
7	Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Human Reproduction, 2003, 18, 323-327.	0.4	539
8	AMH/MIS: what we know already about the gene, the protein and its regulation. Molecular and Cellular Endocrinology, 2003, 211, 21-31.	1.6	216
9	Anti-MÃ $\frac{1}{4}$ llerian hormone levels in serum from human foetuses and children: pattern and clinical interest. Molecular and Cellular Endocrinology, 2003, 211, 55-63.	1.6	81
10	Anti-Müllerian hormone and its role in ovarian function. Molecular and Cellular Endocrinology, 2003, 211, 85-90.	1.6	207
12	Clinical management of low ovarian response to stimulation for IVF: a systematic review. Human Reproduction Update, 2003, 9, 61-76.	5.2	314
14	Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Human Reproduction, 2003, 18, 2368-2374.	0.4	277
15	Early ovarian ageing: a hypothesis: Detection and clinical relevance. Human Reproduction, 2003, 18, 1137-1139.	0.4	152
16	Early ovarian ageing: a hypothesis: What is early ovarian ageing?. Human Reproduction, 2003, 18, 1762-1764.	0.4	16
17	Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Human Reproduction, 2004, 19, 1612-1617.	0.4	135
18	Ovarian Age-Related Responsiveness to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3769-3775.	1.8	35
20	Intercycle variability of ovarian reserve tests: results of a prospective randomized study. Human Reproduction, 2004, 19, 590-595.	0.4	78
21	Early ovarian ageing: are women with polycystic ovaries protected?. Human Reproduction, 2004, 19, 2175-2179.	0.4	36

#	Article	IF	CITATIONS
22	Spontaneous conception in a young woman who had ovarian cortical tissue cryopreserved before chemotherapy and radiotherapy for a Ewing's sarcoma of the pelvis: Case report. Human Reproduction, 2004, 19, 2569-2572.	0.4	63
23	Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Human Reproduction, 2004, 19, 2738-2741.	0.4	173
24	Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients?. BJOG: an International Journal of Obstetrics and Gynaecology, 2004, 111, 1248-1253.	1.1	141
25	Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Molecular Human Reproduction, 2004, 10, 77-83.	1.3	1,053
26	Anti-Muìîllerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive Age. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 318-323.	1.8	448
27	Neuroendocrine physiology of the early and late menopause. Endocrinology and Metabolism Clinics of North America, 2004, 33, 637-659.	1.2	67
28	Early ovarian ageing. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 113, 126-133.	0.5	52
29	Inhibins and adult ovarian function. Molecular and Cellular Endocrinology, 2004, 225, 37-44.	1.6	39
30	Value of the day 3 follicle-stimulating hormone measurement. Fertility and Sterility, 2004, 81, 1486-1488.	0.5	23
31	Serum antim \tilde{A}^{1} /allerian hormone/m \tilde{A}^{1} /allerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility and Sterility, 2004, 82, 1323-1329.	0.5	286
32	Anti-m $\tilde{A}^{1}\!\!/\!\!$ llerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause, 2004, 11, 601-606.	0.8	247
33	Can a blood test predict the onset of menopause?. Menopause, 2004, 11, 585-586.	0.8	6
34	Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Human Reproduction, 2004, 19, 2036-2042.	0.4	131
35	Assessment of ovarian reserve. Current Opinion in Obstetrics and Gynecology, 2004, 16, 231-237.	0.9	58
36	Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 1384-1390.	1.1	237
37	Anti-mullerian hormone as a marker of ovarian reserve*. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 20-24.	0.4	173
38	Development of a sensitive enzyme immunoassay for anti-Mullerian hormone and the evaluation of potential clinical applications in males and females. Clinical Endocrinology, 2005, 63, 267-273.	1.2	98
39	Reproduction and ovarian ageing. The Journal of the British Menopause Society, 2005, 11, 126-131.	1.3	14

#	ARTICLE	IF	Citations
40	Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Human Reproduction Update, 2005, 11, 69-89.	5.2	150
41	Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Human Reproduction Update, 2005, 11, 631-643.	5.2	133
42	Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Human Reproduction, 2005, 20, 3178-3183.	0.4	222
43	A Common Single Nucleotide Polymorphism in Exon 10 of the Human Follicle Stimulating Hormone Receptor Is a Major Determinant of Length and Hormonal Dynamics of the Menstrual Cycle. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4866-4872.	1.8	135
44	Ovarian Reserve. Seminars in Reproductive Medicine, 2005, 23, 248-256.	0.5	39
45	Anti-Mullerian Hormone: Its Role in Follicular Growth Initiation and Survival and as an Ovarian Reserve Marker. Journal of the National Cancer Institute Monographs, 2005, 2005, 18-21.	0.9	87
46	Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatment. Human Reproduction, 2005, 20, 915-922.	0.4	171
47	Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Human Reproduction, 2005, 20, 1569-1572.	0.4	135
48	Anti-Mullerian Hormone in Premenopausal Women and After Spontaneous or Surgically Induced Menopause. Journal of the Society for Gynecologic Investigation, 2005, 12, 545-548.	1.9	99
49	High reproducibility of serum anti-M $\tilde{A}\frac{1}{4}$ llerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Human Reproduction, 2005, 20, 923-927.	0.4	260
50	Predictors of antral follicle count during the reproductive years. Human Reproduction, 2005, 20, 2179-2189.	0.4	52
51	Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Human Reproduction, 2005, 20, 1814-1819.	0.4	148
52	Dynamics of serum anti-MÃ $\frac{1}{4}$ llerian hormone levels during the luteal phase of controlled ovarian hyperstimulation. Human Reproduction, 2005, 20, 747-751.	0.4	40
53	Serum antim \tilde{A}^{1} /4 lerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: A longitudinal study. Fertility and Sterility, 2005, 83, 979-987.	0.5	510
54	Per-follicle measurements indicate that anti-m $\tilde{A}\frac{1}{4}$ llerian hormone secretion is modulated by the extent of follicular development and luteinization and may reflect qualitatively the ovarian follicular status. Fertility and Sterility, 2005, 84, 167-173.	0.5	76
55	Serum mýllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 938-944.	0.5	50
56	Pilot study investigating the age-related decline in ovarian function of regularly menstruating normal women. Fertility and Sterility, 2005, 84, 1462-1469.	0.5	19
57	Serum anti-MÃ $\frac{1}{4}$ llerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Human Reproduction, 2005, 20, 1820-1826.	0.4	235

#	Article	IF	CITATIONS
59	Fertility and ageing. Human Reproduction Update, 2005, 11, 261-276.	5.2	520
60	AMH and AMH receptor defects in persistent MÃ $\frac{1}{4}$ llerian duct syndrome. Human Reproduction Update, 2005, 11, 351-356.	5.2	240
61	Anti-Mýllerian hormone and folliculogenesis. Molecular and Cellular Endocrinology, 2005, 234, 81-86.	1.6	370
62	Management of poor ovarian responders in IVF. Reproductive BioMedicine Online, 2005, 10, 235-246.	1.1	126
63	Influence of oral contraceptive pills on phenotype expression in women with polycystic ovary syndrome. Reproductive BioMedicine Online, 2005, 11, 690-696.	1,1	13
64	Potential Options for Preservation of Fertility in Women. New England Journal of Medicine, 2005, 353, 64-73.	13.9	247
65	The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization. Endocrine Reviews, 2006, 27, 170-207.	8.9	490
66	Serum anti-Mullerian hormone throughout the human menstrual cycle. Human Reproduction, 2006, 21, 3103-3107.	0.4	443
67	RÃ1e de l'AMH (hormone anti-Müllerienne) dans le recrutement folliculaire initial et cyclique. Journal De Gynécologie, Obstétrique Et Biologie De La Reproduction, 2006, 35, 30-34.	0.9	2
68	Anti-mullerian hormone: clinical relevance in assisted reproductive therapy. Annales D'Endocrinologie, 2006, 67, 567-574.	0.6	19
69	Use of ovarian reserve tests for the prediction of ongoing pregnancy in couples with unexplained or mild male infertility. Reproductive BioMedicine Online, 2006, 12, 182-190.	1.1	55
70	Anti-Mýllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reproductive BioMedicine Online, 2006, 12, 695-703.	1.1	84
71	TGF- \hat{l}^2 superfamily members and ovarian follicle development. Reproduction, 2006, 132, 191-206.	1.1	1,000
72	Basal level of anti-Mýllerian hormone is associated with oocyte quality in stimulated cycles. Human Reproduction, 2006, 21, 2022-2026.	0.4	249
73	Early follicular antimüllerian hormone as an indicator of ovarian reserve. Fertility and Sterility, 2006, 85, 592-596.	0.5	213
74	Elevated serum mýllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertility and Sterility, 2006, 85, 1541-1543.	0.5	76
75	Serum anti-m $\tilde{A}\frac{1}{4}$ llerian hormone levels in women with secondary amenorrhea. Fertility and Sterility, 2006, 85, 1547-1549.	0.5	103
76	Absence of follicular phase defect in women with recurrent miscarriage. Fertility and Sterility, 2006, 85, 1784-1790.	0.5	9

#	Article	lF	CITATIONS
77	The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyperresponders to in vitro fertilization. Fertility and Sterility, 2006, 85, 1714-1722.	0.5	42
78	Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertility and Sterility, 2006, 86, 1515-1517.	0.5	50
79	Müllerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochemical and Biophysical Research Communications, 2006, 348, 337-344.	1.0	46
81	Infertility and pregnancy after breast cancer: Current knowledge and future perspectives. Cancer Treatment Reviews, 2006, 32, 417-422.	3.4	46
82	Assessment of ovarian reserveâ€"should we perform tests of ovarian reserve routinely?. Human Reproduction, 2006, 21, 2729-2735.	0.4	98
83	Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool?. Clinical Endocrinology, 2006, 64, 603-610.	1.2	282
84	Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nature Reviews Cancer, 2006, 6, 886-893.	12.8	69
85	Anti-Mul`lerian hormone: a new marker for ovarian function. Reproduction, 2006, 131, 1-9.	1.1	689
86	$M\tilde{A}\frac{1}{4}$ llerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction, 2006, 21, 159-163.	0.4	177
87	The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Human Reproduction, 2006, 21, 2583-2592.	0.4	323
88	Ovarian feedback, mechanism of action and possible clinical implications. Human Reproduction Update, 2006, 12, 557-571.	5.2	143
89	Serum Anti-Mý llerian Hormone Levels Reflect the Size of the Primordial Follicle Pool in Mice. Endocrinology, 2006, 147, 3228-3234.	1.4	320
90	Anti-Muìîllerian Hormone Levels in the Spontaneous Menstrual Cycle Do Not Show Substantial Fluctuation. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4057-4063.	1.8	447
91	Therapy Insight: fertility in women after cancer treatment. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 819-826.	2.9	9
92	The number of small antral follicles (2-6 mm) determines the outcome of endocrine ovarian reserve tests in a subfertile population. Human Reproduction, 2007, 22, 1925-1931.	0.4	116
93	Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Human Reproduction, 2007, 22, 778-785.	0.4	127
94	Fresh human orthotopic ovarian cortex transplantation: long-term results. Human Reproduction, 2007, 22, 786-791.	0.4	37
95	Serum mýllerian-inhibiting substance in Down's syndrome pregnancies. Human Reproduction, 2007, 22, 1017-1020.	0.4	14

#	Article	IF	CITATIONS
96	Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Human Reproduction, 2007, 22, 1996-2005.	0.4	225
97	Hormonal Profile in Women with Polycystic Ovarian Syndrome with or without Type 1 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4742-4746.	1.8	51
98	Growth Factors in Ovarian Development. Seminars in Reproductive Medicine, 2007, 25, 225-234.	0.5	57
99	Predictive Value and Clinical Impact of Basal Follicle-Stimulating Hormone in Subfertile, Ovulatory Women. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2163-2168.	1.8	70
100	Anti-Mul`lerian Hormone Levels in Peripubertal Daughters of Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2739-2743.	1.8	114
101	Serum anti-Mýllerian hormone expression in women with premature ovarian failure. Human Reproduction, 2007, 22, 117-123.	0.4	87
102	Anti-Mul`llerian Hormone Concentrations in the Follicular Fluid of the Preovulatory Follicle Are Predictive of the Implantation Potential of the Ensuing Embryo Obtained byin VitroFertilization. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1796-1802.	1.8	147
103	Premature ovarian failure: a review. Climacteric, 2007, 10, 11-22.	1.1	70
104	The Anti-Mullerian hormone and ovarian cancer. Human Reproduction Update, 2007, 13, 265-273.	5.2	81
105	Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Human Reproduction, 2007, 22, 1837-1840.	0.4	254
106	Anti-MÃ $\frac{1}{4}$ llerian hormone and anti-MÃ $\frac{1}{4}$ llerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Human Reproduction, 2007, 22, 1547-1554.	0.4	97
107	Potential use of biomarkers for analyzing interpopulation and cross-cultural variability in reproductive aging. Menopause, 2007, 14, 668-679.	0.8	9
108	Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertility and Sterility, 2007, 87, 101-106.	0.5	251
109	Antim $\tilde{A}^{1}\!\!/\!4$ llerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertility and Sterility, 2007, 87, 223-226.	0.5	170
110	Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertility and Sterility, 2007, 87, 870-875.	0.5	46
111	Predictors of recovery of ovarian function during weight gain in anorexia nervosa. Fertility and Sterility, 2007, 87, 902-908.	0.5	48
112	Serum and ovarian Mýllerian inhibiting substance, and their decline in reproductive aging. Fertility and Sterility, 2007, 87, 1227-1230.	0.5	17
113	Simple tools for assessment of ovarian reserve (OR): individual ovarian dimensions are reliable predictors of OR. Fertility and Sterility, 2007, 88, 390-395.	0.5	33

#	Article	IF	CITATIONS
114	Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertility and Sterility, 2007, 88, 1645-1652.	0.5	45
115	Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility and Sterility, 2007, 88, 539-546.	0.5	190
116	Fertility preservation for the female oncology patient. Expert Review of Obstetrics and Gynecology, 2007, 2, 155-161.	0.4	0
117	Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles implications for individualization of therapy. Human Reproduction, 2007, 22, 2414-2421.	0.4	357
118	Anti-Mul`lerian Hormone Is a Sensitive Serum Marker for Gonadal Function in Women Treated for Hodgkin's Lymphoma during Childhood. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3869-3874.	1.8	166
119	Anti-Mý llerian hormone levels and antral follicle count in women enrolled in <i>in vitro</i> fertilization cycles: Relationship to lifestyle factors, chronological age and reproductive history. Gynecological Endocrinology, 2007, 23, 486-493.	0.7	102
120	Ageing andÂreproduction: is polycystic ovary syndrome anÂexception?. Annales D'Endocrinologie, 2007, 68, 45-50.	0.6	14
121	Heterozygosity for the Classical Galactosemia Mutation Does Not Affect Ovarian Reserve and Menopausal Age. Reproductive Sciences, 2007, 14, 780-785.	1.1	19
122	Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reproductive Biology and Endocrinology, 2007, 5, 9.	1.4	114
123	Mýllerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF. Reproductive BioMedicine Online, 2007, 14, 450-454.	1.1	30
124	Anti-MÃ $\frac{1}{4}$ llerian hormone as a predictor of IVF outcome. Reproductive BioMedicine Online, 2007, 14, 602-610.	1.1	155
125	Polycystic ovary syndrome: a focus on anti-M $\tilde{A}^{1}/4$ llerian hormone levels. Expert Review of Endocrinology and Metabolism, 2007, 2, 751-758.	1.2	2
126	Relação entre os nÃveis séricos do hormônio anti-Mulleriano, inibina B, estradiol e hormônio folÃculo estimulante no terceiro dia e o status folicular ovariano. Revista Brasileira De Ginecologia E Obstetricia, 2007, 29, .	0.3	3
127	Neuroendocrine Regulation of the Perimenopause Transition. , 2007, , 127-148.		0
128	Predicting the menopause: the role of inhibin B. Trends in Urology Gynaecology & Sexual Health, 2007, 12, 9-10.	0.1	0
129	Antiemetic therapy in cancer patients receiving chemo- or radiotherapy. Trends in Urology Gynaecology & Sexual Health, 2007, 12, 10-11.	0.1	0
130	Mýllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 2007, 196, 77.e1-77.e5.	0.7	36
131	Different ovarian stimulation protocols for women with diminished ovarian reserve. Journal of Assisted Reproduction and Genetics, 2007, 24, 597-611.	1.2	37

#	ARTICLE	IF	Citations
133	Ovarian reserve evaluation: state of the art. Journal of Assisted Reproduction and Genetics, 2008, 25, 311-322.	1.2	50
134	Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. Journal of Assisted Reproduction and Genetics, 2008, 25, 515-521.	1.2	70
136	Does ifosfamide affect gonadal function?. Pediatric Blood and Cancer, 2008, 50, 347-351.	0.8	57
137	<i>Reproductive Health of Adolescent Girls Who Carry the FMR1 Premutation</i> . Annals of the New York Academy of Sciences, 2008, 1135, 99-111.	1.8	51
138	<i>The Ovary</i> . Annals of the New York Academy of Sciences, 2008, 1127, 1-9.	1.8	120
139	Assessment of ovarian reserve with anti-M \tilde{A}^{1} /4 lerian hormone: a comparison of the predictive value of anti-M \tilde{A}^{1} /4 lerian hormone, follicle-stimulating hormone, inhibin B, and age. American Journal of Obstetrics and Gynecology, 2008, 199, 202.e1-202.e8.	0.7	70
140	Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review. Clinical Endocrinology, 2008, 69, 831-844.	1,2	20
141	Correlation of serum anti-M $\tilde{\text{A}}^{1}$ /Allerian hormone with accelerated follicle loss following 4-vinylcyclohexene diepoxide-induced follicle loss in mice. Reproductive Toxicology, 2008, 26, 116-122.	1.3	35
142	A Functional Anti-Müllerian Hormone Gene Polymorphism Is Associated with Follicle Number and Androgen Levels in Polycystic Ovary Syndrome Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1310-1316.	1.8	64
143	What can we expect if we measure hormones in eumenorrhoeic infertile patients?. Reproductive BioMedicine Online, 2008, 16, 621-626.	1.1	5
144	Anti-MÃ $\frac{1}{4}$ llerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?. Reproductive BioMedicine Online, 2008, 16, 664-670.	1.1	113
145	Evaluation of different markers of the ovarian reserve in patients presenting with premature ovarian failure. Molecular and Cellular Endocrinology, 2008, 282, 95-100.	1.6	38
146	Anti-Mýllerian hormone and ovarian dysfunction. Trends in Endocrinology and Metabolism, 2008, 19, 340-347.	3.1	183
147	Mýllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertility and Sterility, 2008, 89, 1364-1370.	0.5	150
148	Anti-MÃ1/4llerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. Fertility and Sterility, 2008, 89, 586-591.	0.5	105
149	Follicular fluid anti-Mýllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles. Fertility and Sterility, 2008, 89, 860-867.	0.5	36
150	Evaluation of the relationship between follicular fluid oxidative stress, ovarian hormones, and response to gonadotropin stimulation. Fertility and Sterility, 2008, 89, 912-921.	0.5	99
151	Anti-Mýllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertility and Sterility, 2008, 89, 1670-1676.	0.5	121

#	Article	IF	CITATIONS
152	Comparison of serum and plasma measurements of MÃ $\frac{1}{4}$ llerian inhibiting substance. Fertility and Sterility, 2008, 89, 1836-1837.	0.5	6
153	Relationship of bariatric surgery to MÃ $^{1}/_{4}$ llerian-inhibiting substance levels. Fertility and Sterility, 2008, 90, 221-224.	0.5	33
154	Evaluation of anti-MÃ $\frac{1}{4}$ llerian hormone as a test for the prediction of ovarian reserve. Fertility and Sterility, 2008, 90, 737-743.	0.5	171
155	Anti-Mý llerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility, 2008, 90, 2203-2210.	0.5	76
157	The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls. Human Reproduction, 2008, 23, 1416-1423.	0.4	41
158	Relevance of anti-Mullerian hormone measurement in a routine IVF program. Human Reproduction, 2008, 23, 1359-1365.	0.4	199
159	Relationship of Serum Antimul`llerian Hormone Concentration to Age at Menopause. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2129-2134.	1.8	232
160	Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Human Reproduction, 2008, 24, 982-990.	0.4	155
161	Cellular and molecular aspects of ovarian follicle ageing. Human Reproduction Update, 2008, 14, 131-142.	5.2	342
162	Anti-Mullerian Hormone and Inhibin B in the Definition of Ovarian Aging and the Menopause Transition. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3478-3483.	1.8	342
163	Variants in the ACVR1 gene are associated with AMH levels in women with polycystic ovary syndrome. Human Reproduction, 2008, 24, 241-249.	0.4	31
164	The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Human Reproduction, 2008, 23, 952-957.	0.4	136
165	Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Human Reproduction, 2008, 23, 674-678.	0.4	109
167	Utility of serum antim $\tilde{A}\frac{1}{4}$ llerian hormone/M $\tilde{A}\frac{1}{4}$ llerian-Inhibiting Substance for predicting ovarian reserve in older women. Menopause, 2008, 15, 824-826.	0.8	1
168	Premature ovarian failure: predictability of intermittent ovarian function and response to ovulation induction agents. Current Opinion in Obstetrics and Gynecology, 2008, 20, 416-420.	0.9	46
169	The Prediction and Management of Poor Responders in ART. , 0, , 428-442.		1
170	Analysis of Serum Levels of Anti-Mýllerian Hormone, Inhibin B, Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Follicle-Stimulating Hormone with Respect to Age and Menopausal Status. Journal of Korean Medical Science, 2008, 23, 104.	1.1	30
171	Serum Anti-M \tilde{A}^{1} /Allerian Hormone and Inhibin B Levels at Ovulation Triggering Day Can Predict the Number of Immature Oocytes Retrieved in In Vitro Fertilization Cycles. Journal of Korean Medical Science, 2008, 23, 657.	1.1	15

#	Article	IF	CITATIONS
172	Normal Aging and the Menopausal Transition: What to Expect. Key Issues in Mental Health, 2009, , 1-17.	0.6	2
174	Screening for early ovarian ageing., 0,, 201-210.		1
175	Is ovarian reserve diminished after laparoscopic ovarian drilling?. Gynecological Endocrinology, 2009, 25, 159-165.	0.7	84
176	Molecular Mechanisms Underlying the Activation of Mammalian Primordial Follicles. Endocrine Reviews, 2009, 30, 438-464.	8.9	351
177	Anti-Mullerian Hormone Is an Endocrine Marker of Ovarian Gonadotropin-Responsive Follicles and Can Help to Predict Superovulatory Responses in the Cow. Biology of Reproduction, 2009, 80, 50-59.	1.2	206
178	Female contraception over 40. Human Reproduction Update, 2009, 15, 599-612.	5.2	40
179	Anti-Mul`lerian Hormone, Inhibin B, and Antral Follicle Count in Young Women with Ovarian Failure. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 786-792.	1.8	207
180	The predictive value of the automated quantification of the number and size of small antral follicles in women undergoing ART. Human Reproduction, 2009, 24, 2124-2132.	0.4	24
181	Roles for Transforming Growth Factor Beta Superfamily Proteins in Early Folliculogenesis. Seminars in Reproductive Medicine, 2009, 27, 014-023.	0.5	105
182	Prospective Case-Control Study of Serum Mullerian Inhibiting Substance and Breast Cancer Risk. Journal of the National Cancer Institute, 2009, 101, 1501-1509.	3.0	26
183	Anti-Mullerian hormone (AMH): what do we still need to know?. Human Reproduction, 2009, 24, 2264-2275.	0.4	285
184	Gonadotropin stimulation as a challenge to calibrate cisplatin induced ovarian damage in the female rat. Reproductive Toxicology, 2009, 28, 556-562.	1.3	9
185	Serum anti-MÃ $\frac{1}{4}$ llerian hormone predicts ovarian response and cycle outcome in IVF patients. Journal of Assisted Reproduction and Genetics, 2009, 26, 383-389.	1.2	61
186	Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. Pediatric Blood and Cancer, 2009, 53, 296-302.	0.8	79
187	Carbohydrate complexity and proportion of serum FSH isoforms reflect pituitary–ovarian activity in perimenopausal women and depot medroxyprogesterone acetate users. Clinical Endocrinology, 2009, 71, 558-565.	1.2	11
188	The Mammalian Ovary from Genesis to Revelation. Endocrine Reviews, 2009, 30, 624-712.	8.9	630
189	The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertility and Sterility, 2009, 91, 705-714.	0.5	442
190	Correlation of antim $\tilde{A}\frac{1}{4}$ llerian hormone and baseline follicle-stimulating hormone levels. Fertility and Sterility, 2009, 91, 2616-2619.	0.5	66

#	Article	IF	CITATIONS
191	Circulating basal anti-Mýllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertility and Sterility, 2009, 92, 1586-1593.	0.5	232
192	Negligible serum anti-m \tilde{A}^{1} /allerian hormone: pregnancy and birth after a 1-month course of an oral contraceptive, ovarian hyperstimulation, and intracytoplasmic sperm injection. Fertility and Sterility, 2009, 92, 395.e9-395.e12.	0.5	13
193	Testing ovarian reserve to predict age at menopause. Maturitas, 2009, 63, 280-291.	1.0	114
194	Aging of the human ovary and testis. Molecular and Cellular Endocrinology, 2009, 299, 2-13.	1.6	129
195	Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reproductive Biology and Endocrinology, 2009, 7, 100.	1.4	71
196	Biological versus chronological ovarian age: implications for assisted reproductive technology. Reproductive Biology and Endocrinology, 2009, 7, 101.	1.4	122
197	Ovarian Aging: Mechanisms and Clinical Consequences. Endocrine Reviews, 2009, 30, 465-493.	8.9	875
198	Medical Approaches to Ovarian Stimulation for Infertility., 2009,, 689-724.		4
199	The Ovarian Life Cycle. , 2009, , 155-190.		15
200	Anti muellerian hormone serum levels in women with endometriosis: A case–control study. Gynecological Endocrinology, 2009, 25, 713-716.	0.7	72
201	Serum antimýllerian hormone is not predictive of oocyte quality in vitro fertilization. Annales D'Endocrinologie, 2009, 70, 230-234.	0.6	35
202	L'hormone antimüllérienne sérique n'est pas prédictive de la qualité ovocytaire en fécondati vitro. Annales D'Endocrinologie, 2009, 70, e29-e34.	ion in 0.6	1
203	Clinical Implications of Ovarian Reserve Testing. Obstetrical and Gynecological Survey, 2009, 64, 120-128.	0.2	14
204	Serum antim $\tilde{A}^{1}\!\!/\!\!4$ llerian hormone predicts ovarian reserve in a monkey model. Menopause, 2009, 16, 597-601.	0.8	29
205	Influence of lifestyle factors on fertility rate. Expert Review of Obstetrics and Gynecology, 2009, 4, 635-646.	0.4	1
207	Prognostic Role of Ovarian Reserve Testing. Current Women's Health Reviews, 2010, 6, 267-272.	0.1	O
208	Effect of Obesity on Parameters of Ovarian Reserve in Premenopausal Women. Journal of Obstetrics and Gynaecology Canada, 2010, 32, 687-690.	0.3	56
209	The role of anti-Mýllerian hormone assessment in assisted reproductive technology outcome. Current Opinion in Obstetrics and Gynecology, 2010, 22, 193-201.	0.9	94

#	Article	IF	CITATIONS
210	The effect of diet and cardiovascular risk on ovarian aging in cynomolgus monkeys (Macaca) Tj ETQq0 0 0 rgBT /0	Overlock 1	.0 <u>Jf</u> 50 742 1
211	The impact of smoking on antimÃ $\frac{1}{4}$ llerian hormone levels in women aged 38 to 50 years. Menopause, 2010, 17, 571-576.	0.8	117
213	Smoking and AMH levels in women with normal reproductive history. Archives of Gynecology and Obstetrics, 2010, 282, 215-219.	0.8	36
214	Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wiener Klinische Wochenschrift, 2010, 122, 519-524.	1.0	37
215	Maternal antimullerian hormone levels do not predict fetal aneuploidy. Journal of Assisted Reproduction and Genetics, 2010, 27, 409-414.	1.2	32
216	Early follicular anti-mullerian hormone as a predictor of ovarian response during ICSI cycles. Middle East Fertility Society Journal, 2010, 15, 281-287.	0.5	3
217	Anti-Mýllerian hormone in polycystic ovary syndrome and normo-ovulatory women: Correlation with clinical, hormonal and ultrasonographic parameters. Middle East Fertility Society Journal, 2010, 15, 253-258.	0.5	17
218	Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductiveâ€aged breast cancer survivors. Cancer, 2010, 116, 592-599.	2.0	105
219	The correlation of the antral follicle count and Serum anti-mullerian hormone. Journal of the Turkish German Gynecology Association, 2010, 11, 212-215.	0.2	18
220	Influence of preterm birth and small birth size on serum anti-Mþllerian hormone levels in young adult women. European Journal of Endocrinology, 2010, 163, 937-944.	1.9	43
222	Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecological Endocrinology, 2010, 26, 152-160.	0.7	64
223	Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Human Reproduction, 2010, 25, 221-227.	0.4	295
224	Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Human Reproduction, 2010, 25, 1520-1527.	0.4	94
225	ls polycystic ovary syndrome an exception for reproductive aging?. Human Reproduction, 2010, 25, 1775-1781.	0.4	89
226	Anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction. Human Reproduction, 2010, 25, 2597-2604.	0.4	41
229	Anti-MÃ 1 /Allerian hormone and polycystic ovary syndrome: a mountain too high?. Reproduction, 2010, 139, 825-833.	1.1	175
230	Anti-M \tilde{A}^{1} /allerian hormone (AMH): Regulator and marker of ovarian function. Annales D'Endocrinologie, 2010, 71, 191-197.	0.6	65
231	Fertility Preservation in Adolescents and Young Adults With Cancer. Journal of Clinical Oncology, 2010, 28, 4831-4841.	0.8	287

#	Article	IF	CITATIONS
235	The use of anti-Mýllerian hormone and antral follicle count to predict the potential of oocytes and embryos. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 150, 166-170.	0.5	105
236	Change in the ovarian environment after hysterectomy as assessed by ovarian arterial blood flow indices and serum anti-Mýllerian hormone levels. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 151, 82-85.	0.5	38
237	True ovarian volume is underestimated by two-dimensional transvaginal ultrasound measurement. Fertility and Sterility, 2010, 93, 995-998.	0.5	41
238	The impact on ovarian reserve after laparoscopic ovarian cystectomy versus three-stage management in patients with endometriomas: a prospective randomized study. Fertility and Sterility, 2010, 94, 71-77.	0.5	189
239	Impact of laparoscopic cystectomy on ovarian reserve: serial changes of serum anti-MÃ $\frac{1}{4}$ llerian hormone levels. Fertility and Sterility, 2010, 94, 343-349.	0.5	239
240	Assay reproducibility and within-person variation of Mýllerian inhibiting substance. Fertility and Sterility, 2010, 94, 301-304.	0.5	20
241	The antral follicle count: practical recommendations for better standardization. Fertility and Sterility, 2010, 94, 1044-1051.	0.5	338
242	Repetitive oocyte donation does not decrease serum anti-M $\tilde{A}\frac{1}{4}$ llerian hormone levels. Fertility and Sterility, 2010, 94, 905-912.	0.5	22
243	Association study of AMH and AMHRII polymorphisms with unexplained infertility. Fertility and Sterility, 2010, 94, 1244-1248.	0.5	31
244	Early follicle development during the luteal-follicular transition affects the predictability of serum follicle-stimulating hormone but not antim $\tilde{A}\frac{1}{4}$ llerian hormone levels on cycle day 3. Fertility and Sterility, 2010, 94, 1827-1831.	0.5	4
245	Racial and ethnic differences in reproductive potential across the life cycle. Fertility and Sterility, 2010, 93, 681-690.	0.5	83
246	Anti-Mý llerian hormone testing is useful for individualization of stimulation protocols in oocyte donors. Reproductive BioMedicine Online, 2010, 20, 42-47.	1.1	16
247	Effect of cigarette smoking upon reproductive hormones in women of reproductive age: a retrospective analysis. Reproductive BioMedicine Online, 2010, 20, 861-865.	1.1	49
248	Normal serum concentrations of anti-MÃ 1 /4llerian hormone in women with regular menstrual cycles. Reproductive BioMedicine Online, 2010, 21, 463-469.	1.1	91
251	Antimullerian hormone levels after laparoscopic endometrioma stripping surgery. Gynecological Endocrinology, 2010, 26, 468-472.	0.7	71
252	Serum Anti-M \tilde{A}^{1} /Allerian Hormone Concentrations in Prepubertal Girls with and without Premature Adrenarche: The Influence of Body Mass Index. Hormone Research in Paediatrics, 2010, 74, 207-211.	0.8	14
253	Anti-Mullerian hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles. Human Fertility, 2011, 14, 246-253.	0.7	29
254	Ovarian reserve in young women with low birth weight and normal puberty: a pilot case–control study. Gynecological Endocrinology, 2011, 27, 641-644.	0.7	11

#	ARTICLE	IF	CITATIONS
255	Medical approaches to preservation of fertility in female cancer patients. Expert Opinion on Pharmacotherapy, 2011, 12, 387-396.	0.9	35
256	Anti-MÃ $\frac{1}{4}$ llerian hormone testing is useful for individualization of stimulation protocols in oocyte donors. Reproductive BioMedicine Online, 2011, 22, S88-S93.	1.1	8
257	FSH and Its Second Messenger cAMP Stimulate the Transcription of Human Anti-M $\tilde{A}^{1/4}$ llerian Hormone in Cultured Granulosa Cells. Molecular Endocrinology, 2011, 25, 645-655.	3.7	63
258	Effects of laparoscopic surgery on serum anti-m $\tilde{A}\frac{1}{4}$ llerian hormone levels in reproductive-aged women with endometrioma. Gynecological Endocrinology, 2011, 27, 733-736.	0.7	73
259	Does 75 IU difference improve the cycle performance in poor responders? Comparison of daily 375 versus 450 IU gonadotrophin doses. Gynecological Endocrinology, 2011, 27, 1001-1006.	0.7	2
260	Age-related distribution of basal serum AMH level in women of reproductive age and a presumably healthy cohort. Fertility and Sterility, 2011, 95, 832-834.	0.5	60
261	Changes in plasma m $\tilde{A}^{1}\!\!/\!\!4$ llerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal women. Fertility and Sterility, 2011, 95, 1790-1793.	0.5	6
262	Antim $\tilde{A}^{1}\!\!/\!4$ llerian hormone as a predictor of controlled ovarian hyperstimulation outcome: comparison of two commercial immunoassay kits. Fertility and Sterility, 2011, 95, 2602-2604.	0.5	13
263	Serum antim $\tilde{A}\frac{1}{4}$ llerian hormone in healthy premenopausal women. Fertility and Sterility, 2011, 95, 2718-2721.	0.5	54
264	The phenotype of polycystic ovary syndrome ameliorates with aging. Fertility and Sterility, 2011, 96, 1259-1265.	0.5	107
265	Serum Anti-M \tilde{A}^{1} /Allerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum Follicle Stimulating Hormone (FSH) levels. Medical Hypotheses, 2011, 77, 649-653.	0.8	26
266	Effect on ovarian reserve of laparoscopic bipolar electrocoagulation versus laparotomic hemostatic sutures during unilateral ovarian cystectomy. International Journal of Gynecology and Obstetrics, 2011, 114, 69-72.	1.0	43
268	The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reproductive BioMedicine Online, 2011, 23, 411-420.	1.1	118
269	Laparoscopic stripping of endometriomas negatively affects ovarian follicular reserve even if performed by experienced surgeons. Reproductive BioMedicine Online, 2011, 23, 740-746.	1.1	134
270	Age specific serum anti-MÃ $\frac{1}{4}$ llerian hormone levels in 1,298 Korean women with regular menstruation. Clinical and Experimental Reproductive Medicine, 2011, 38, 93.	0.5	45
271	The clinical significance of anti-MÃ $^1\!\!/4$ llerian hormone evaluation in gynecological endocrinology. Hormones, 2011, 10, 95-103.	0.9	44
273	Serum anti-Müllerian hormone as a predictive marker of polycystic ovarian syndrome. International Journal of General Medicine, 2011, 4, 759.	0.8	19
274	Serum anti-MÃ $^1\!\!$ /llerian hormone levels as a predictor of the ovarian response and IVF outcomes. Clinical and Experimental Reproductive Medicine, 2011, 38, 153.	0.5	29

#	Article	IF	CITATIONS
275	New concepts in ovarian stimulation. , 0, , 54-72.		0
276	The effect of chemotherapy and radiotherapy on the human reproductive system. , 0, , 11-22.		0
277	The Progressive Simplification of the Infertility Evaluation. Obstetrical and Gynecological Survey, 2011, 66, 31-41.	0.2	10
278	Predicting age at menopause from serum antim $\tilde{A}\frac{1}{4}$ llerian hormone concentration. Menopause, 2011, 18, 766-770.	0.8	93
279	Is There a Place for AMH Testing in Canada?. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 628-632.	0.3	0
280	Antimýllerian Hormone as a Predictor of Natural Fecundability in Women Aged 30–42 Years. Obstetrics and Gynecology, 2011, 117, 798-804.	1.2	146
281	Normal Ovarian Function and Assessment of Ovarian Reserve in Children and Young People. , 2011 , , $331-349$.		1
282	Fertility preservation in girls and young women. Clinical Endocrinology, 2011, 75, 409-419.	1.2	72
283	Iron overload is associated with low anti-m $\tilde{A}\frac{1}{4}$ llerian hormone in women with transfusion-dependent \hat{I}^2 -thalassaemia. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 825-831.	1.1	24
284	Micro-dose flare-up gonadotrophin-releasing hormone (GnRH) agonist vs. flexible gonadotrophin-releasing hormone (GnRH) antagonist protocol in patient with poor ovarian reserve. Middle East Fertility Society Journal, 2011, 16, 272-277.	0.5	3
285	Mýllerian inhibiting substance is anterogradely transported and does not attenuate avulsion-induced death of hypoglossal motor neurons. Experimental Neurology, 2011, 231, 304-308.	2.0	10
286	Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment. Journal of Assisted Reproduction and Genetics, 2011, 28, 501-508.	1.2	34
288	Serum antiâ€müllerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index. Reproductive Medicine and Biology, 2011, 10, 113-120.	1.0	12
289	Postnatal Developmental Changes in the Pituitary-Ovarian Axis in Preterm and Term Infant Girls. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3432-3439.	1.8	149
290	Anti-Mullerian hormone in short girls born small for gestational age and the effect of growth hormone treatment. Human Reproduction, 2011, 26, 898-903.	0.4	14
291	Anti-Mýllerian hormone confirms the novel classification of female functional androgenization including polycystic ovary syndrome. European Journal of Endocrinology, 2011, 165, 323-330.	1.9	12
292	Regulation of Anti-M $\tilde{A}^{1/4}$ llerian Hormone Production in the Cow: A Multiscale Study at Endocrine, Ovarian, Follicular, and Granulosa Cell Levels 1. Biology of Reproduction, 2011, 84, 560-571.	1,2	116
293	Serum and follicular fluid anti-mullerian hormone concentrations at the time of follicle puncture and reproductive outcome. Journal of the Turkish German Gynecology Association, 2011, 13, 21-6.	0.2	5

#	Article	IF	CITATIONS
294	Anti-M \tilde{A} 1 4llerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2532-2539.	1.8	303
295	Fertility and Ovarian Function in High-Dose Estrogen-Treated Tall Women. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1098-1105.	1.8	58
296	Serum anti-Mullerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. Human Reproduction, 2011, 26, 671-677.	0.4	94
297	Trisomic pregnancy and elevated FSH: implications for the oocyte pool hypothesis. Human Reproduction, 2011, 26, 1537-1550.	0.4	43
298	First assessment of menstrual cycle function and reproductive endocrine status in Samoan women. Human Reproduction, 2011, 26, 2518-2524.	0.4	15
299	Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers. Human Reproduction, 2011, 26, 2185-2191.	0.4	34
300	Normal serum concentrations of anti-MÃ $\frac{1}{4}$ llerian hormone in a population of fertile women in their first trimester of pregnancy. Human Reproduction, 2011, 26, 3431-3436.	0.4	18
301	Pretreatment Serum Anti-Mýllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1336-1343.	1.8	200
302	Anti-M \tilde{A} - $\frac{1}{4}$ llerian Hormone in Women with Polycystic Ovary Syndrome Before and After Therapy with Metformin. Hormone and Metabolic Research, 2011, 43, 723-727.	0.7	23
303	Ovarian reserve tests. Journal of Human Reproductive Sciences, 2011, 4, 108.	0.4	72
304	Animal age, weight and estrus cycle stage impact the quality of in vitro grown follicles. Human Reproduction, 2011, 26, 2473-2485.	0.4	36
305	Reproductive Late Effects in Female Survivors of Childhood Cancer. Obstetrics and Gynecology International, 2012, 2012, 1-7.	0.5	20
306	Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma. Annals of Oncology, 2012, 23, 1626-1632.	0.6	16
307	The Anti Mullerian Hormone- A Novel Marker for Assessing the Ovarian Reserve in Women with Regular Menstrual Cycles. Journal of Clinical and Diagnostic Research JCDR, 2012, 6, 1636-9.	0.8	20
308	Anti-Mullerian Hormone: A Potential New Tool in Epidemiologic Studies of Female Fecundability. American Journal of Epidemiology, 2012, 175, 245-249.	1.6	28
309	Oocyte retrieval and selection. , 2012, , 96-113.		0
310	Maternal smoking during pregnancy and reproductive health of daughters: a follow-up study spanning two decades. Human Reproduction, 2012, 27, 3593-3600.	0.4	48
311	Individual serum levels of anti-Mullerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Human Reproduction, 2012, 27, 861-866.	0.4	115

#	Article	IF	CITATIONS
312	Endocrine characteristics of ART cycles. , 2012, , 99-114.		1
313	Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?. Human Reproduction, 2012, 27, 2494-2502.	0.4	113
314	Initial investigation of the infertile couple. , 2012, , 31-40.		0
315	Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review. Human Reproduction Update, 2012, 18, 12-28.	5.2	52
316	Evaluation of ovarian reserve in infertile patients. Journal of the Turkish German Gynecology Association, 2012, 13, 196-203.	0.2	27
317	Ovarian Reserve Assessment for Infertility Investigation. ISRN Obstetrics & Gynecology, 2012, 2012, 1-10.	1.2	28
318	Gonadotoxicity of Cancer Therapies in Pediatric and Reproductive-Age Females. , 2012, , 3-14.		8
319	Data-driven assessment of the human ovarian reserve. Molecular Human Reproduction, 2012, 18, 79-87.	1.3	93
320	Anti-MÃ $\frac{1}{4}$ llerian hormone in women with polycystic ovary syndrome. Korean Journal of Obstetrics & Gynecology, 2012, 55, 315.	0.1	6
321	Anti-Mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries. Human Reproduction, 2012, 27, 854-860.	0.4	40
322	Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the Follicular Output RaTe (FORT) may predict in vitro fertilization-embryo transfer outcome. Human Reproduction, 2012, 27, 1066-1072.	0.4	80
323	Quantification of anti-Mullerian hormone (AMH) in dried blood spots: validation of a minimally invasive method for assessing ovarian reserve. Human Reproduction, 2012, 27, 2503-2508.	0.4	26
324	Premenopausal antim $\tilde{A}\frac{1}{4}$ llerian hormone concentration is associated with subsequent atherosclerosis. Menopause, 2012, 19, 1353-1359.	0.8	49
325	The role of antiâ€müllerian hormone as a predictor of ovarian function. The Obstetrician and Gynaecologist, 2012, 14, 161-166.	0.2	6
326	The Impact of Excision of Ovarian Endometrioma on Ovarian Reserve: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3146-3154.	1.8	415
327	Contribution of the rate of change of antim $\tilde{A}\frac{1}{4}$ llerian hormone in estimating time to menopause for late reproductive-age women. Fertility and Sterility, 2012, 98, 1254-1259.e2.	0.5	90
328	Low concentration of circulating antim $\tilde{A}\frac{1}{4}$ llerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertility and Sterility, 2012, 98, 1602-1608.e2.	0.5	139
329	Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reproductive BioMedicine Online, 2012, 25, 612-619.	1.1	126

#	ARTICLE	IF	CITATIONS
330	Female Fertility Assessment. Current Obstetrics and Gynecology Reports, 2012, 1, 174-181.	0.3	3
331	Measuring anti-MÃ $\frac{1}{4}$ llerian hormone for the assessment of ovarian reserve: When and for whom is it indicated? Maturitas, 2012, 71, 28-33.	1.0	116
332	Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility, 2012, 97, 28-38.e25.	0.5	1,494
333	Impact of cancer therapies on ovarian reserve. Fertility and Sterility, 2012, 97, 134-140.e1.	0.5	173
334	The association between circulating levels of antim $\tilde{A}\frac{1}{4}$ llerian hormone and follicle number, androgens, and menstrual cycle characteristics in young women. Fertility and Sterility, 2012, 97, 779-785.	0.5	64
335	Assessment of FSHR variants and antim $\tilde{A}\frac{1}{4}$ llerian hormone in infertility patients with a reduced ovarian response to gonadotropin stimulation. Fertility and Sterility, 2012, 97, 1169-1175.e1.	0.5	26
337	Age at menarche and parity are independently associated with Antiâ€MÃ⅓llerian hormone, a marker of ovarian reserve, in filipino young adult women. American Journal of Human Biology, 2012, 24, 739-745.	0.8	30
338	Serum Anti-Mýllerian Hormone Levels in Healthy Females: A Nomogram Ranging from Infancy to Adulthood. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4650-4655.	1.8	203
339	Waiting for an elevated <scp>FSH</scp> – Too late a marker of reduced ovarian reserve?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 460-464.	0.4	14
340	The role of antiâ€MÃ1⁄4llerian hormone in female fertility and infertility – an overview. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1252-1260.	1.3	79
342	Anti-Mullerian Hormone as a Predictor of Time to Menopause in Late Reproductive Age Women. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1673-1680.	1.8	245
343	Anti-Mýllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nature Reviews Endocrinology, 2012, 8, 331-341.	4.3	210
344	Current understanding of ovarian aging. Science China Life Sciences, 2012, 55, 659-669.	2.3	78
345	Is there any correlation between amh and obesity in premenopausal women?. Archives of Gynecology and Obstetrics, 2012, 286, 661-665.	0.8	46
346	Anti-Müllerian Hormone Serum Values and Ovarian Reserve: Can It Predict a Decrease in Fertility after Ovarian Stimulation by ART Cycles?. PLoS ONE, 2012, 7, e44571.	1.1	34
347	Impact of hysterectomy on ovarian reserve in early postoperative period. Korean Journal of Obstetrics & Gynecology, 2012, 55, 17.	0.1	1
348	Clinical application of anti-MÃ $\frac{1}{4}$ llerian hormone as a predictor of controlled ovarian hyperstimulation outcome. Clinical and Experimental Reproductive Medicine, 2012, 39, 176.	0.5	13
349	The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Human Reproduction, 2012, 27, 1829-1839.	0.4	81

#	Article	IF	CITATIONS
350	Ageâ€related distributions of antiâ€Müllerian hormone level and antiâ€Müllerian hormone models. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 970-975.	1.3	36
351	Anti-Mullerian-hormone levels during pregnancy and postpartum. Reproductive Biology and Endocrinology, $2013,11,60.$	1.4	67
352	Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? - A pilot study. Reproductive Biology and Endocrinology, 2013, 11, 28.	1.4	21
353	Effects of bipolar electrocoagulation versus suture after laparoscopic excision of ovarian endometrioma on the ovarian reserve and outcome of <i>in vitro</i> fertilization. Journal of Obstetrics and Gynaecology Research, 2013, 39, 1246-1252.	0.6	35
354	Antim \tilde{A} ¹ /4 lerian hormone as predictor of reproductive outcome in subfertile women with elevated basal follicle-stimulating hormone levels: a follow-up study. Fertility and Sterility, 2013, 100, 831-838.e2.	0.5	23
355	AntimÃ $\frac{1}{4}$ llerian hormone levels decrease in women using combined contraception independently of administration route. Fertility and Sterility, 2013, 99, 1305-1310.	0.5	100
356	AntimÃ $\frac{1}{4}$ llerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertility and Sterility, 2013, 99, 1469-1475.	0.5	82
357	Anti-MÃ $\frac{1}{4}$ llerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 167, 194-198.	0.5	20
358	Influence of various tubal surgeries to serum antimullerian hormone level and outcome of the subsequent IVF-ET treatment. Gynecological Endocrinology, 2013, 29, 345-349.	0.7	33
359	Anti-Mullerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment. Human Reproduction, 2013, 28, 1899-1907.	0.4	73
360	Impact of Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation on Women's Fertility. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 704-710.	0.2	24
361	Impact of tubal ligation on ovarian reserve as measured by anti-MÃ $^1\!/\!4$ llerian hormone levels: a prospective cohort study. Contraception, 2013, 88, 700-705.	0.8	14
362	Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4629-4638.	1.8	105
363	Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age. Journal of Assisted Reproduction and Genetics, 2013, 30, 1421-1429.	1.2	22
364	Evaluation of ovarian function in 35–40-year-old women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 170, 165-170.	0.5	7
365	Fertility outcome of breast cancer and Hodgkin's lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists. Gynecological Endocrinology, 2013, 29, 729-734.	0.7	2
366	Anti-Mýllerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy. Gynecological Endocrinology, 2013, 29, 357-360.	0.7	9
367	The ageing ovary and uterus: new biological insights. Human Reproduction Update, 2013, 19, 67-83.	5.2	204

#	ARTICLE	IF	Citations
368	Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertility and Sterility, 2013, 100, 1704-1708.	0.5	130
369	Endocrine sequelae and metabolic syndrome in adult long-term survivors of childhood acute myeloid leukemia. Leukemia Research, 2013, 37, 367-371.	0.4	24
370	One-year follow-up of serum antim $\tilde{A}\frac{1}{4}$ llerian hormone levels in patients with cystectomy: are different sequential changes due to \hat{A} different mechanisms causing damage to the ovarian reserve?. Fertility and Sterility, 2013, 100, 516-522.e3.	0.5	93
371	Comparison of serum anti-Mullerian hormone levels following hysterectomy and myomectomy for benign gynaecological conditions. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 171, 368-371.	0.5	27
372	Comparison of follicular fluid and serum anti-Mullerian hormone levels as predictors of the outcome of assisted reproductive treatment. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 252-256.	0.5	13
373	Serum anti-MÃ 1 /4llerian hormone levels are lower in reproductive-age women with Crohn's disease compared to healthy control women. Journal of Crohn's and Colitis, 2013, 7, e29-e34.	0.6	65
374	Ovarian endometrioma: guidelines for selection of cases for surgical treatment or expectant management. Expert Review of Obstetrics and Gynecology, 2013, 8, 29-55.	0.4	5
375	Decreased ovarian function is associated with obesity in very long-term female survivors of childhood cancer. European Journal of Endocrinology, 2013, 168, 905-912.	1.9	26
376	Modeling Age at Menopause Using Serum Concentration of Anti-Mullerian Hormone. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 729-735.	1.8	125
377	Can Anti-M \tilde{A}^{1} /4llerian Hormone Predict the Diagnosis of Polycystic Ovary Syndrome? A Systematic Review and Meta-Analysis of Extracted Data. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3332-3340.	1.8	230
378	Serum anti-mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 170, 157-161.	0.5	57
379	Regulation of anti-MÃ $\frac{1}{4}$ llerian hormone production in domestic animals. Reproduction, Fertility and Development, 2013, 25, 1.	0.1	115
380	Human blood contains both the uncleaved precursor of anti-M \tilde{A}^{1} /allerian hormone and a complex of the NH ₂ - and COOH-terminal peptides. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E1241-E1247.	1.8	50
381	Ovarian Antral Follicle Subclasses and Anti-Müllerian Hormone During Normal Reproductive Aging. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1602-1611.	1.8	106
382	Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age. Human Reproduction, 2013, 28, 247-255.	0.4	49
383	Genetic variation may modify ovarian reserve in female childhood cancer survivors. Human Reproduction, 2013, 28, 1069-1076.	0.4	39
384	Predicting Reproductive Age with Biomarkers of Ovarian Reserve—How (and What) Are We Measuring?. Seminars in Reproductive Medicine, 2013, 31, 416-426.	0.5	13
385	The combined use of antimullerian hormone and age to predict the ovarian response to controlled ovarian hyperstimulation in poor responders: A novel approach. Journal of Human Reproductive Sciences, 2013, 6, 259.	0.4	6

#	Article	IF	Citations
386	Serum Anti-MÃ $\frac{1}{4}$ llerian Hormone Levels in Patients with Epithelial Ovarian Cancer. International Journal of Endocrinology, 2013, 2013, 1-6.	0.6	5
387	Potential Mechanisms for Racial and Ethnic Differences in Antim $\tilde{A}\frac{1}{4}$ llerian Hormone and Ovarian Reserve. International Journal of Endocrinology, 2013, 2013, 1-7.	0.6	64
388	Benign ovarian cysts in reproductive-age women undergoing assisted reproductive technology treatment. Open Journal of Obstetrics and Gynecology, 2013, 03, 17-22.	0.1	3
389	Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Human Reproduction Update, 2013, 19, 26-36.	5.2	372
390	Pregnancy following ovarian induction in a patient with premature ovarian failure and undetectable serum antiâ€ <scp>M</scp> üllerian hormone. Journal of Obstetrics and Gynaecology Research, 2013, 39, 1070-1072.	0.6	3
391	Ovarian reserve following uterine artery embolization in women of reproductive age: A preliminary report. Minimally Invasive Therapy and Allied Technologies, 2013, 22, 45-49.	0.6	13
392	Pubertal development and fertility in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO-AML study. Pediatric Blood and Cancer, 2013, 60, 1988-1995.	0.8	25
393	Characteristics and outcome of pediatric non-hodgkin lymphoma patients with ovarian infiltration at presentation. Pediatric Blood and Cancer, 2013, 60, 2054-2059.	0.8	8
394	Preoperative Serum Anti-Mullerian Hormone Level in Women with Ovarian Endometrioma and Mature Cystic Teratoma. Yonsei Medical Journal, 2013, 54, 921.	0.9	51
395	Women's Fecundability and Factors Affecting It. , 2013, , 193-207.		1
396	Endometriosis of the ovary., 0,, 189-198.		1
397	Role of antim $\tilde{A}^{1}\!\!/\!\!4$ llerian hormone as a biomarker of the menopausal transition. Menopause, 2013, 20, 218-222.	0.8	12
398	Fertility Preservation., 2014,, 791-821.e7.		3
400	The Ovarian Life Cycle. , 2014, , 157-191.e8.		7
401	Anti-Mý llerian Hormone Levels in the Follicular Fluid of the Preovulatory Follicle: A Predictor for Oocyte Fertilization and Quality of Embryo. Journal of Korean Medical Science, 2014, 29, 1266.	1.1	23
402	The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies. Obstetrics and Gynecology Science, 2014, 57, 478.	0.6	5
404	Interleukin-1 deficiency prolongs ovarian lifespan in mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12492-12497.	3.3	85
405	Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF. Human Reproduction, 2014, 29, 1049-1057.	0.4	74

#	Article	IF	Citations
406	Anti-Mýllerian hormone levels in women with polycystic ovarian syndrome compared with normal women of reproductive age in China. Gynecological Endocrinology, 2014, 30, 126-129.	0.7	14
407	Decreasing Quality of the New Generations of Anti-MÃ $\frac{1}{4}$ llerian Hormone Assays. BioMed Research International, 2014, 2014, 1-7.	0.9	9
408	Anti-Mý llerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause. Human Reproduction, 2014, 29, 584-591.	0.4	63
409	Anti-M \tilde{A} - $1/4$ llerian hormone as an ovarian reserve marker in young cancer women who undergo ovarian tissue cryopreservation. Future Oncology, 2014, 10, 1343-1351.	1.1	6
410	Reproductive treatment choices for women with low anti-MÃ $\frac{1}{4}$ llerian hormone. Evidence Based Women S Health Journal, 2014, 4, 23-29.	0.0	0
411	Evaluation of ovarian reserve in Hashimoto's thyroiditis. Gynecological Endocrinology, 2014, 30, 708-711.	0.7	31
412	Early and late endocrine effects in pediatric central nervous system diseases. Journal of Pediatric Rehabilitation Medicine, 2014, 7, 281-294.	0.3	8
413	AMH and AMHR2 genetic variants in Chinese women with primary ovarian insufficiency and normal age at natural menopause. Reproductive BioMedicine Online, 2014, 29, 311-318.	1.1	26
414	Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 27-42.	2.0	68
415	Anti-M \tilde{A} 1/4llerian Hormone Levels Before and after Uterine Artery Embolization: A Preliminary Report. Fertility and Sterility, 2014, 101, e11.	0.5	0
416	Mini-dose long gonadotropin-releasing hormone (GnRH) agonist versus agonist flare stimulation protocol for in vitro fertilization poor responders. Middle East Fertility Society Journal, 2014, 19, 287-292.	0.5	1
417	The root of reduced fertility in aged women and possible therapentic options: Current status and future perspects. Molecular Aspects of Medicine, 2014, 38, 54-85.	2.7	117
418	Antral follicle count as a marker of ovarian biological age to reflect the background risk of fetal aneuploidy. Human Reproduction, 2014, 29, 1337-1343.	0.4	20
419	Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. Journal of Assisted Reproduction and Genetics, 2014, 31, 213-220.	1.2	47
420	Serum AMH Levels in Women With a History of Preeclampsia Suggest a Role for Vascular Factors in Ovarian Aging. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 579-586.	1.8	37
421	Decreased serum anti-Mullerian hormone levels in girls with newly diagnosed cancer. Human Reproduction, 2014, 29, 337-342.	0.4	56
423	The Ovarian Reserve of Primordial Follicles and the Dynamic Reserve of Antral Growing Follicles: What Is the Link?1. Biology of Reproduction, 2014, 90, 85.	1.2	158
424	Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle. Human Reproduction, 2014, 29, 592-600.	0.4	35

#	Article	IF	CITATIONS
425	Medical Approaches to Ovarian Stimulation for Infertility. , 2014, , 701-733.e8.		2
426	Basal serum anti-müllerian hormone and antral follicle count are predictors of ovarian response for Asian women in Singapore. Asian Pacific Journal of Reproduction, 2014, 3, 169-175.	0.2	3
427	Evaluation of the effects of single or multiple dose methotrexate administration, salpingectomy on ovarian reserve of rat with the measurement of anti-Müllerian hormone (AMH) levels and histological analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 181, 205-209.	0.5	16
428	Elevated LH levels draw a stronger distinction than AMH in premature ovarian insufficiency. Climacteric, 2014, 17, 197-203.	1.1	12
429	AMH: An ovarian reserve biomarker in assisted reproduction. Clinica Chimica Acta, 2014, 437, 175-182.	0.5	67
430	Positive cross talk between FOXL2 and antim $\tilde{A}\frac{1}{4}$ llerian hormone regulates ovarian reserve. Fertility and Sterility, 2014, 102, 847-855.e1.	0.5	27
431	Anti-MÃ $\frac{1}{4}$ llerian hormone: ovarian reserve testing and its potential clinical implications. Human Reproduction Update, 2014, 20, 688-701.	5.2	491
432	Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reproductive Biology and Endocrinology, 2014, 12, 26.	1.4	74
433	Lipid profiles and ovarian reserve status: a longitudinal study. Human Reproduction, 2014, 29, 2522-2529.	0.4	50
434	Effect of Surgery for Endometrioma on Ovarian Function. Journal of Minimally Invasive Gynecology, 2014, 21, 203-209.	0.3	35
435	Argon beam coagulator versus cystectomy for endometrioma treatment in infertile women and the impact on ovarian reserve. A case control study. Middle East Fertility Society Journal, 2014, 19, 22-26.	0.5	4
436	Antim $\tilde{A}^{1}\!\!/\!4$ llerian hormone as a measure of reproductive function in female childhood cancer survivors. Fertility and Sterility, 2014, 101, 227-231.	0.5	56
437	Age-specific serum antim \tilde{A}^{1} /allerian hormone levels in women with and without polycystic ovary syndrome. Fertility and Sterility, 2014, 102, 230-236.e2.	0.5	59
438	Enzyme-linked immunosorbent assay measurements of antimýllerian hormone (AMH) in human blood are a composite of the uncleaved and bioactive cleaved forms of AMH. Fertility and Sterility, 2014, 101, 846-850.e1.	0.5	25
439	Predictive value of antral follicle count and anti-M \tilde{A}^{1} /allerian hormone for follicle and oocyte developmental competence during the early prepubertal period in a sheep model. Reproduction, Fertility and Development, 2014, 26, 1094.	0.1	33
440	Iron stores and obesity are negatively associated with ovarian volume and anti-M \tilde{A}^{1} /allerian hormone levels in women with polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 686-692.	0.5	18
441	Anti-Mullerian-Hormone during pregnancy and peripartum using the new Beckman Coulter AMH Gen II Assay. Reproductive Biology and Endocrinology, 2015, 13, 86.	1.4	18
442	Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity. Reproductive Biology and Endocrinology, 2015, 13, 106.	1.4	23

#	Article	IF	CITATIONS
443	Age-related trends in anti-Mullerian hormone serum level in women with unilateral and bilateral ovarian endometriomas prior to surgery. Reproductive Biology and Endocrinology, 2015, 13, 128.	1.4	33
444	Anti-Mýllerian Hormone and Lifestyle, Reproductive, and Environmental Factors Among Women in Rural South Africa. Epidemiology, 2015, 26, 429-435.	1.2	43
445	Comparing four ovarian reserve markers – associations with ovarian response and live births after assisted reproduction. Acta Obstetricia Et Gynecologica Scandinavica, 2015, 94, 1056-1063.	1.3	39
446	Circulating antiâ€Müllerian hormone levels in relation to nutritional status and selected adipokines levels in polycystic ovary syndrome. Clinical Endocrinology, 2015, 83, 98-104.	1.2	35
447	An approach to fertility preservation in prepubertal and postpubertal females: A critical review of current literature. Pediatric Blood and Cancer, 2015, 62, 935-939.	0.8	33
448	An Analysis of the Influence of Selected Genetic and Hormonal Factors on the Occurrence of Depressive Symptoms in Late-Reproductive-Age Women. International Journal of Environmental Research and Public Health, 2015, 12, 3547-3563.	1.2	3
449	Fertility Preservation in Reproductive-Age Women Facing Gonadotoxic Treatments. Current Oncology, 2015, 22, 294-304.	0.9	28
450	Serum Anti-MÃ 1 /allerian Hormone Levels before Surgery in Patients with Ovarian Endometriomas Compared to Other Benign Ovarian Cysts. Journal of Menopausal Medicine, 2015, 21, 142.	0.3	16
451	Maternal antimullerian hormone as a predictor of fetal aneuploidy occurring in an early pregnancy loss. Obstetrics and Gynecology Science, 2015, 58, 494.	0.6	14
452	AMH mutations with reduced in vitro bioactivity are related to premature ovarian insufficiency. Human Reproduction, 2015, 30, 1196-1202.	0.4	50
453	Placenta expresses anti-MÃ $\frac{1}{4}$ llerian hormone and its receptor: Sex-related difference in fetal membranes. Placenta, 2015, 36, 731-737.	0.7	19
454	Anti-m $\tilde{A}\frac{1}{4}$ llerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 195, 188-192.	0.5	3
455	Antim \tilde{A}^{1} /4 lerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility and Sterility, 2015, 103, 119-130.e3.	0.5	153
456	Maternal serum anti-Mýllerian hormone at $11\hat{a}$ €"13 weeks \hat{a} €™ gestation in the prediction of preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2015, 28, 865-868.	0.7	15
457	Effects of Resveratrol on Ovarian Morphology, Plasma Anti-Mullerian Hormone, IGF-1 Levels, and Oxidative Stress Parameters in a Rat Model of Polycystic Ovary Syndrome. Reproductive Sciences, 2015, 22, 942-947.	1.1	50
458	Investigation of the effects of unilateral total salpingectomy on ovarian proliferating cell nuclear antigen and follicular reserve: experimental study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 188, 56-60.	0.5	15
459	Anti-Müllerian Hormone and Assessment of Ovarian Reserve After Ovarian Toxic Treatment: A Systematic Narrative Review. Reproductive Sciences, 2015, 22, 519-526.	1.1	39
460	Bone mineral density after childhood cancer in 346 long-term adult survivors of childhood cancer. Osteoporosis International, 2015, 26, 521-529.	1.3	44

#	Article	IF	CITATIONS
461	Comparison of markers of ovarian reserve between patients with complete m $\tilde{A}^{1}/4$ llerian agenesis and \hat{A} age-matched fertile and infertile controls. Fertility and Sterility, 2015, 104, 176-179.	0.5	3
462	Changes in Markers of Ovarian Reserve After Laparoscopic Ovarian Cystectomy. Journal of Minimally Invasive Gynecology, 2015, 22, 997-1003.	0.3	29
463	Effect of Anti-Mýllerian hormone (AMH) and bone morphogenetic protein 15 (BMP-15) on steroidogenesis in primary-cultured human luteinizing granulosa cells through Smad5 signalling. Journal of Assisted Reproduction and Genetics, 2015, 32, 1079-1088.	1.2	35
464	Menopause prediction and potential implications. Maturitas, 2015, 82, 257-265.	1.0	57
465	AMH as Predictor of Premature Ovarian Insufficiency: A Longitudinal Study of 120 Turner Syndrome Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1030-E1038.	1.8	89
466	Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study. Reproductive BioMedicine Online, 2015, 31, 347-355.	1.1	13
467	Management of endometrial modifications in perimenopausal women. Medicine and Pharmacy Reports, 2015, 88, 101-110.	0.2	12
468	Gene variants associated with age at menopause are also associated with polycystic ovary syndrome, gonadotrophins and ovarian volume. Human Reproduction, 2015, 30, 1697-1703.	0.4	19
469	An assessment of anti-MÃ $\frac{1}{4}$ llerian hormone in predicting mating outcomes in female hamsters that have undergone natural and chemically-accelerated reproductive aging. General and Comparative Endocrinology, 2015, 214, 56-61.	0.8	8
470	Role of ovarian reserve markers, antim $\tilde{A}^{1}\!\!/\!\!$ llerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages. Fertility and Sterility, 2015, 103, 1221-1227.e2.	0.5	23
471	Anti Mý llerian hormone levels before and after uterine artery embolization: A preliminary report. Minimally Invasive Therapy and Allied Technologies, 2015, 24, 242-245.	0.6	20
472	The BOC ELISA, a ruminant-specific AMH immunoassay, improves the determination of plasma AMH concentration and its correlation with embryo production in cattle. Theriogenology, 2015, 84, 1397-1404.	0.9	6
474	Anti-Mý llerian hormone levels as a predictor of ovarian reserve in systemic lupus erythematosus patients: a review. Revista Brasileira De Reumatologia, 2015, 55, 363-367.	0.7	0
476	Circulating AMH Reflects Ovarian Morphology by Magnetic Resonance Imaging and 3D Ultrasound in 121 Healthy Girls. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 880-890.	1.8	50
477	Anti-MÃ $\frac{1}{4}$ llerian hormone, the holy grail for fertility counselling in the general population?. Human Reproduction, 2015, 30, 2257-2258.	0.4	9
479	Age-related Infertility. Obstetrics and Gynecology Clinics of North America, 2015, 42, 15-25.	0.7	132
480	Elevated serum thyroid-stimulating hormone is associated with decreased anti-MÃ $^1\!/\!4$ llerian hormone in infertile women of reproductive age. Journal of Assisted Reproduction and Genetics, 2015, 32, 243-247.	1.2	31
481	Follicular Development. , 2015, , 947-995.		12

#	Article	IF	Citations
482	Anti-MÃ $\frac{1}{4}$ llerian hormone as a marker of premature ovarian aging in autoimmune thyroid disease. Gynecological Endocrinology, 2015, 31, 165-168.	0.7	41
483	Anti-M \tilde{A} 1/4llerian hormone as a possible predictor of fecundability in subfertile women over 38 years: a retrospective cohort study. Gynecological Endocrinology, 2015, 31, 22-25.	0.7	7
484	Anti-Mullerian hormone normogram in an Irish subfertile population. Irish Journal of Medical Science, 2015, 184, 213-218.	0.8	9
485	Revised criteria for <scp>PCOS</scp> in <scp>WHO G</scp> roup <scp>II</scp> anovulatory infertility – a revival of hypothalamic amenorrhoea?. Clinical Endocrinology, 2015, 82, 584-591.	1.2	22
486	Study of ovarian reserve parameters in infertile women of different age groups. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2016, , 2116-2121.	0.0	2
487	Hydrogen-rich Water Exerting a Protective Effect on Ovarian Reserve Function in a Mouse Model of Immune Premature Ovarian Failure Induced by Zona Pellucida 3. Chinese Medical Journal, 2016, 129, 2331-2337.	0.9	15
488	Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center. Archives of Endocrinology and Metabolism, 2016, 60, 486-491.	0.3	10
489	Menopausal Age and Chronic Diseases in Elderly Women: A Cross-Sectional Study in Northeast China. International Journal of Environmental Research and Public Health, 2016, 13, 936.	1.2	21
490	Does AMH Reflect Follicle Number Similarly in Women with and without PCOS?. PLoS ONE, 2016, 11, e0146739.	1.1	22
491	Fertility of patients with polycystic ovary syndrome undergoing in vitro fertilization by age. International Journal of Gynecology and Obstetrics, 2016, 135, 91-95.	1.0	9
492	Hypogonadism and Sex Steroid Replacement Therapy in Girls with Turner Syndrome. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 542-550.	0.3	11
493	Age-specific anti-MÃ $^{1}\!\!$ /llerian hormone and electrocardiographic silent coronary artery disease. Climacteric, 2016, 19, 344-348.	1.1	9
494	Does anti-MÃ $\frac{1}{4}$ llerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study. Human Reproduction, 2016, 31, 1579-1587.	0.4	70
495	Association between vascular health and ovarian ageing in type 1 diabetes mellitus. Human Reproduction, 2016, 31, 1354-1362.	0.4	15
496	N-acetylcysteine leads to greater ovarian protection than enoxaparin sodium in a rat ovarian torsion model. Reproductive BioMedicine Online, 2016, 33, 93-101.	1.1	19
497	La hormona antim \tilde{A}^{1} /alleriana como marcador de funci \tilde{A}^{3} n ov \tilde{A}_{1} rica. Revista Argentina De Endocrinologia Y Metabolismo, 2016, 53, 106-113.	0.0	1
498	New automated antim $\tilde{A}\frac{1}{4}$ llerian hormone assays are more reliable than the manual assay in patients with reduced antral follicle count. Fertility and Sterility, 2016, 106, 1800-1806.	0.5	30
499	The effects of uterine artery embolization on ovarian reserve. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, 172-176.	0.5	40

#	Article	IF	CITATIONS
500	Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study. Reproductive BioMedicine Online, 2016, 33, 506-512.	1.1	24
501	Ovario-protective effects of genistein against cyclophosphamide toxicity in rats: Role of anti-m¼llerian hormone and oestradiol. European Journal of Pharmacology, 2016, 789, 163-171.	1.7	30
502	Association of <i>BRCA1</i> Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. Journal of Adolescent and Young Adult Oncology, 2016, 5, 337-343.	0.7	53
503	FXTAS, FXPOI, and Other Premutation Disorders. , 2016, , .		12
504	Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. Journal of Clinical Oncology, 2016, 34, 3440-3450.	0.8	173
505	Circulating Anti-Mþllerian Hormone Levels in Daughters of Women with and without Polycystic Ovary Syndrome. Hormone Research in Paediatrics, 2016, 85, 372-378.	0.8	9
506	Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss. Human Reproduction, 2016, 32, 193-200.	0.4	26
507	Interrelationships among reproductive hormones and antral follicle count in human menstrual cycles. Endocrine Connections, 2016, 5, 98-107.	0.8	8
508	Comparison of early postoperative decline of serum antiMýllerian hormone levels after unilateral laparoscopic ovarian cystectomy between patients categorized according to histologic diagnosis. Taiwanese Journal of Obstetrics and Gynecology, 2016, 55, 641-645.	0.5	15
509	Comparison of the long-term effects of single-dose methotrexate and salpingectomy on ovarian reserve in terms of anti-mýllerian hormone levels. Human Fertility, 2016, 19, 262-267.	0.7	5
510	Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced?. Human Reproduction, 2016, 31, 2651-2659.	0.4	29
511	A predictive scheme to assess the outcome of IVF/ICSI cycles in poor responders. Evidence Based Women S Health Journal, 2016, 6, 90-94.	0.0	O
512	Fertility in women of late reproductive age: the role of serum anti-Mýllerian hormone (AMH) levels in its assessment. Journal of Endocrinological Investigation, 2016, 39, 1259-1265.	1.8	65
513	Anti-Müllerian Hormone in Female Adolescent Cancer Patients Before, During, and After Completion of Therapy: A Pilot Feasibility Study. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 599-603.	0.3	19
514	New insights in the selection and management of cancer patients applicants for ovarian tissue cryopreservation. Gynecological Endocrinology, 2016, 32, 881-885.	0.7	10
515	Novel correlates between antimù⁄4llerian hormone and menstrualÂcycle characteristics inÂAfrican-American women (23–35Âyears-old). Fertility and Sterility, 2016, 106, 443-450.e2.	0.5	15
516	Anti-Mý llerian hormone gene polymorphism is associated with androgen levels in Chinese polycystic ovary syndrome patients with insulin resistance. Journal of Assisted Reproduction and Genetics, 2016, 33, 199-205.	1.2	13
517	Plasma Anti-Mýllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 854-860.	1.1	23

#	ARTICLE	IF	Citations
518	The ovarian response to standard gonadotropin stimulation is influenced by AMHRII genotypes. Gynecological Endocrinology, 2016, 32, 641-645.	0.7	12
519	Diabetes and Menopause. Current Diabetes Reports, 2016, 16, 20.	1.7	46
520	Patients with cancer at the margins of reproductive age had reduced levels of antiâ€Mýllerian hormone compared with patients experiencing infertility. International Journal of Gynecology and Obstetrics, 2016, 133, 226-229.	1.0	3
521	Antiâ€MÃ⅓llerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?. Reproductive Medicine and Biology, 2016, 15, 127-136.	1.0	52
522	A specific immunoassay for proAMH, the uncleaved proprotein precursor of anti-Müllerian hormone. Molecular and Cellular Endocrinology, 2016, 419, 165-171.	1.6	18
523	Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Archives of Gynecology and Obstetrics, 2016, 293, 447-456.	0.8	44
524	Fertility after uterine artery embolization: a review. Minimally Invasive Therapy and Allied Technologies, 2016, 25, 1-7.	0.6	47
525	Mathematical modelling of decline in follicle pool during female reproductive ageing. Mathematical Medicine and Biology, 2016, 33, 107-121.	0.8	7
526	Value of <i>in situ</i> ovarian volume measured during cesarean delivery to assess the potential of diminished ovarian reserve. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 1016-1022.	0.7	3
527	Repeatability of antral follicle counts and anti-Mýllerian hormone and their associations determined at an unknown stage of follicular growth and an expected day of follicular wave emergence in dairy cows. Theriogenology, 2017, 92, 90-94.	0.9	21
528	A putative role for anti-M $\tilde{\text{A}}$ /4llerian hormone (AMH) in optimising ovarian reserve expenditure. Journal of Endocrinology, 2017, 233, R1-R13.	1.2	54
529	Anti-Mý llerian hormone kinetics in pregnancy and post-partum: a systematic review. Reproductive BioMedicine Online, 2017, 34, 522-533.	1.1	13
531	Antral Follicles Count and Anti-Müllerian Hormone Levels after Gonadotoxic Chemotherapy in Patients with Breast Cancer: Cohort Study. Revista Brasileira De Ginecologia E Obstetricia, 2017, 39, 162-168.	0.3	9
532	Left–right differences in ovarian volume and antral follicle count in 1423 women of reproductive age. Gynecological Endocrinology, 2017, 33, 320-323.	0.7	12
533	Age-associated and deslorelin-induced declines in serum anti-MÃ $\frac{1}{4}$ llerian hormone concentrations in female cheetahs, Acinonyx jubatus. General and Comparative Endocrinology, 2017, 250, 54-57.	0.8	9
534	Ovarian Endocrinology. , 2017, , 3-35.		0
535	Follistatin during pregnancy and its potential role as an ovarian suppressing agent. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 212, 150-154.	0.5	8
536	Premature Ovarian Insufficiency. , 2017, , 197-215.		0

#	ARTICLE	IF	CITATIONS
537	Assessment of ovarian reserve after hysterectomy: Laparoscopic vs. non-laparoscopic surgery. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 210, 54-57.	0.5	11
538	c-JUN Dimerization Protein 2 (JDP2) Is a Transcriptional Repressor of Follicle-stimulating Hormone \hat{l}^2 (FSH \hat{l}^2) and Is Required for Preventing Premature Reproductive Senescence in Female Mice. Journal of Biological Chemistry, 2017, 292, 2646-2659.	1.6	23
540	Ovarian Stem Cell Nests in Reproduction and Ovarian Aging. Cellular Physiology and Biochemistry, 2017, 43, 1917-1925.	1.1	34
541	What are the likely IVF/ICSI outcomes if there is a discrepancy between serum AMH and FSH levels? A multicenter retrospective study. Journal of Gynecology Obstetrics and Human Reproduction, 2017, 46, 629-635.	0.6	11
542	Regulation of AMH by oocyte-specific growth factors in human primary cumulus cells. Reproduction, 2017, 154, 745-753.	1.1	26
543	Ageâ€stratified thresholds of antiâ€Mýllerian hormone improve prediction of polycystic ovary syndrome over a populationâ€based threshold. Clinical Endocrinology, 2017, 87, 733-740.	1.2	26
544	Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys. Human Reproduction, 2017, 32, 923-936.	0.4	51
545	Maternal serum anti-M $\tilde{A}^{1}\!\!/\!\!4$ llerian hormone in Sudanese women with preeclampsia. BMC Research Notes, 2017, 10, 217.	0.6	4
546	Ovarian reserve is preserved in Behçet's disease. International Journal of Rheumatic Diseases, 2017, 20, 2070-2076.	0.9	7
547	EFFECT OF IRON OVERLOAD AND IRON CHELATORS ON ANTI-MÜLLERIAN HORMONE LEVEL IN EGYPTIAN FEMALE PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 263.	0.3	0
548	The predictive value of serum concentrations of anti-MÃ $\frac{1}{4}$ llerian hormone for oocyte quality, fertilization, and implantation. Jornal Brasileiro De Reproducao Assistida, 2017, 21, 176-182.	0.3	29
549	The Protective Effect of N-Acetylcysteine on Ionizing Radiation Induced Ovarian Failure and Loss of Ovarian Reserve in Female Mouse. BioMed Research International, 2017, 2017, 1-11.	0.9	19
550	Evaluation of three-dimensional SonoAVC ultrasound for antral follicle count in infertile women: its agreement with conventional two-dimensional ultrasound and serum levels of anti-Müllerian hormone. Reproductive Biology and Endocrinology, 2017, 15, 96.	1.4	14
551	Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocrine Journal, 2017, 64, 531-541.	0.7	25
552	25-Hydroxyvitamin D (25(OH)D) and biomarkers of ovarian reserve. Menopause, 2018, 25, 811-816.	0.8	15
553	Chronological age vs biological age: a retrospective analysis on age-specific serum anti-M $\tilde{A}^{1/4}$ llerian hormone levels for 3280 females in reproductive center clinic. Gynecological Endocrinology, 2018, 34, 890-894.	0.7	9
554	Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center. Endocrine, 2018, 60, 167-174.	1.1	9
555	Maternal nutrient restriction impairs young adult offspring ovarian signaling resulting in reproductive dysfunction and follicle lossâ€. Biology of Reproduction, 2018, 98, 664-682.	1.2	20

#	Article	IF	CITATIONS
556	AntimÃ $\frac{1}{4}$ Ilerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012â \in 2013. Fertility and Sterility, 2018, 109, 258-265.	0.5	53
557	Low estradiol responses in oocyte donors undergoing gonadotropin stimulation do not influence clinical outcomes. Journal of Assisted Reproduction and Genetics, 2018, 35, 1675-1682.	1.2	6
558	Ovarian function, fertility and reproductive lifespan in cancer patients. Expert Review of Endocrinology and Metabolism, 2018, 13, 125-136.	1.2	52
559	The Diagnostic Value of Anti-Müllerian Hormone in Early Post Menarche Adolescent Girls with Polycystic Ovarian Syndrome. Journal of Pediatric and Adolescent Gynecology, 2018, 31, 362-366.	0.3	6
560	Neonatal exposure to estradiol valerate reprograms the rat ovary androgen receptor and anti-M $\tilde{A}\frac{1}{4}$ llerian hormone to a polycystic ovary phenotype. Reproductive Toxicology, 2018, 75, 127-135.	1.3	7
561	Anti-Mýllerian hormone levels before and after uterine artery embolization. Minimally Invasive Therapy and Allied Technologies, 2018, 27, 186-190.	0.6	16
562	Ovarian and Uterine Functions in Female Survivors of Childhood Cancers. Oncologist, 2018, 23, 214-224.	1.9	42
563	Anti-Mþllerian Hormone: genetic and environmental effects. Clinica Chimica Acta, 2018, 476, 123-129.	0.5	29
564	Anti-Mýllerian Hormone (AMH) May Stall Ovarian Cortex Function Through Modulation of Hormone Receptors Other Than the AMH Receptor. Reproductive Sciences, 2018, 25, 1218-1223.	1,1	12
565	Identification of Novel Mutations of <i>AMH </i> Gene in Iraqi Women with Premature Ovarian Failure. OnLine Journal of Biological Sciences, 2018, 18, 446-452.	0.2	0
568	Anti-Mullerian hormone before and after uterine artery embolisation in reproductive-age women seeking treatment for symptomatic fibroids. South African Journal of Obstetrics and Gynaecology, 2018, 24, 57.	0.1	2
569	Anti-M \tilde{A}^{1} /4llerian hormone as a predictor of reproductive potential. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 385-390.	1.2	27
570	Modifiable Risk Factors for the Development of Breast Cancer in Young Women. Cancer Journal (Sudbury, Mass), 2018, 24, 275-284.	1.0	15
571	The likelihood of achieving pregnancy through timed coitus in young infertile women with decreased ovarian reserve. Clinical and Experimental Reproductive Medicine, 2018, 45, 31-37.	0.5	10
572	Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. BMC Cancer, 2018, 18, 930.	1.1	13
573	Gonadal function and pubertal development in patients with Silverâ€"Russell syndrome. Human Reproduction, 2018, 33, 2122-2130.	0.4	6
574	Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study. Thyroid, 2018, 28, 1702-1707.	2.4	29
575	Premature ovarian insufficiency and early depletion of the ovarian reserve in the monogenic Mulibrey nanism disorder. Human Reproduction, 2018, 33, 1254-1261.	0.4	11

#	Article	IF	CITATIONS
576	Anti-mÃ $\frac{1}{4}$ llerian hormone levels are associated with live birth rates in ART, but the predictive ability of anti-m $\frac{3}{4}$ llerian hormone is modest. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 225, 199-204.	0.5	28
577	Presence of anti-M \tilde{A}^{1} /4llerian hormone (AMH) during follicular development in the porcine ovary. PLoS ONE, 2018, 13, e0197894.	1.1	29
578	Comparative mRNA and miRNA expression in European mouflon (Ovis musimon) and sheep (Ovis aries) provides novel insights into the genetic mechanisms for female reproductive success. Heredity, 2019, 122, 172-186.	1.2	21
579	Ovarian Life Cycle. , 2019, , 167-205.e9.		11
580	Medical Approaches to Ovarian Stimulation for Infertility., 2019,, 743-778.e7.		3
581	Fertility Preservation. , 2019, , 857-886.e6.		2
582	Ovarian reserve parameters and response toÂcontrolled ovarian stimulation in infertile patients. Pakistan Journal of Medical Sciences, 2019, 35, 958-962.	0.3	11
583	Comparison of Automated Anti-Mþllerian Hormone Assays and Antral Follicle Count in Predicting Ovarian Response During Ovarian Stimulation. Fertility & Reproduction, 2019, 01, 99-105.	0.0	3
584	Determination of the relationship between serum antiâ€MÃ⅓llerian hormone level and superovulatory response in Simmental cows. Reproduction in Domestic Animals, 2019, 54, 1322-1329.	0.6	4
585	Ovarian follicle resilience in mice orally dosed with methoxychlor: Are reproductive impacts possible in mammals as ecological receptors?. Ecological Indicators, 2019, 106, 105502.	2.6	1
586	Preoperative serum anti-M $\tilde{A}^{1/4}$ llerian hormone level is a potential predictor of ovarian endometrioma severity and postoperative fertility. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 240, 113-120.	0.5	11
587	Gonadal Failure Is Common in Long-Term Survivors of Childhood High-Risk Neuroblastoma Treated With High-Dose Chemotherapy and Autologous Stem Cell Rescue. Frontiers in Endocrinology, 2019, 10, 555.	1.5	11
588	Young women's opinions on the use of a blood test to predict the possibility of premature ovarian failure: a qualitative study. Human Fertility, 2021, 24, 304-314.	0.7	3
589	Changes in Anti-MÃ $\frac{1}{4}$ llerian Hormone and Inhibin B in Children Treated for Cancer. Journal of Adolescent and Young Adult Oncology, 2019, 8, 281-290.	0.7	12
590	Anti-Mýllerian Hormone in PCOS: A Review Informing International Guidelines. Trends in Endocrinology and Metabolism, 2019, 30, 467-478.	3.1	130
591	A 10-year longitudinal study of evaluation of ovarian reserve in women with transfusion-dependent beta thalassaemia major. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 238, 38-43.	0.5	8
592	Overtime trend of thyroid hormones and thyroid autoimmunity and ovarian reserve: a longitudinal population study with a 12-year follow up. BMC Endocrine Disorders, 2019, 19, 47.	0.9	24
593	Understanding Follicular Output Rate (FORT) and its Implications for POSEIDON Criteria. Frontiers in Endocrinology, 2019, 10, 246.	1.5	28

#	Article	IF	CITATIONS
594	Anti-Müllerian Hormone Expression in Endometrial Cancer Tissue. International Journal of Molecular Sciences, 2019, 20, 1325.	1.8	9
595	Serum anti mullerian hormone and renalase levels in predicting the risk of preeclampsia. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 188-191.	0.5	7
596	Effect of laparoscopic endometrioma cystectomy on anti-MÃ $^1\!/\!4$ llerian hormone (AMH) levels. Gynecological Endocrinology, 2019, 35, 494-497.	0.7	20
597	RELATIONSHIP BETWEEN SERUM ANTIMULLERIAN HORMONE, FOLLICULAR STIMULATING HORMONE, AND LUTEAL HORMONE LEVELS WITH OVARIAN FOLLICULAR STATUS ON DAY THREE OF MENSTRUAL CYCLE. International Research Journal of Pharmacy, 2019, 9, 75-80.	0.0	0
598	Serum anti-Mullerian hormone and homocysteine in premenopausal females with and without cardiovascular disease. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2019, 8, 479.	0.0	0
599	Neoadjuvant Treatment With MÃ $\frac{1}{4}$ llerian-Inhibiting Substance Synchronizes Follicles and Enhances Superovulation Yield. Journal of the Endocrine Society, 2019, 3, 2123-2134.	0.1	12
600	Association between ovarian reserve and preeclampsia: a cohort study. BMC Pregnancy and Childbirth, 2019, 19, 432.	0.9	4
601	Regulation of Follicle Formation and Development by Ovarian Signaling Pathways. , 2019, , 23-49.		7
602	Reproductive ageingâ€"turning back the clock?. Irish Journal of Medical Science, 2019, 188, 161-167.	0.8	13
603	Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer. Thyroid, 2020, 30, 580-587.	2.4	25
604	Evaluation of relationship between HbA1c levels and ovarian reserve in patients with type 1 diabetes mellitus. Gynecological Endocrinology, 2020, 36, 426-430.	0.7	4
605	Maternal serum concentration of anti-M $\tilde{A}^{1/4}$ llerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment. PLoS ONE, 2020, 15, e0239779.	1.1	5
606	DuoStim: a new option for fertility preservation for a woman with Turner syndrome. Gynecological Endocrinology, 2020, 36, 1144-1148.	0.7	7
607	Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and Sterility, 2020, 114, 1151-1157.	0.5	144
608	A Comprehensive Overview of Common Polymorphic Variants in Genes Related to Polycystic Ovary Syndrome. Reproductive Sciences, 2020, 28, 2399-2412.	1.1	21
609	Determinants of Maternal Renin-Angiotensin-Aldosterone-System Activation in Early Pregnancy: Insights From 2 Cohorts. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3505-3517.	1.8	29
610	Lack of effect of short-term DHEA supplementation on the perimenopausal ovaryâ€. Biology of Reproduction, 2020, 103, 1209-1216.	1.2	3
611	The anti-Mullerian hormone as a predictor of early pregnancy loss in subfertile women. Systems Biology in Reproductive Medicine, 2020, 66, 370-377.	1.0	6

#	Article	IF	CITATIONS
612	Association between a history of depression and anti-m $\tilde{A}^{1}/4$ llerian hormone among late-reproductive aged women: the Harvard study of moods and cycles. Women's Midlife Health, 2020, 6, 9.	0.5	5
613	Anti-Mýllerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies. Medicine (United States), 2020, 99, e20523.	0.4	1
614	A Gatekeeping Role of ESR2 to Maintain the Primordial Follicle Reserve. Endocrinology, 2020, 161 , .	1.4	26
615	Inhibin B as a screening tool for early detection and treatment monitoring of central precocious puberty. Gynecological Endocrinology, 2020, 36, 768-771.	0.7	8
616	Comparison of pregnancy outcomes following intrauterine insemination in young women with decreased versus normal ovarian reserve. Fertility and Sterility, 2020, 113, 788-796.e4.	0.5	13
617	Anti-Mý llerian Hormone and Ovarian Morphology in Women With Hypothalamic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2008-e2014.	1.8	17
618	Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1862-e1871.	1.8	66
619	Relationship between the timing of the first postpartum ovulation and antral follicle counts in Holstein cows. Journal of Ovarian Research, 2020, 13, 7.	1.3	3
620	Comparison of serum antimüllerian hormone levels after robotic-assisted vs. laparoscopic approach for ovarian cystectomy in endometrioma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 249, 9-13.	0.5	11
621	Next Steps Toward AMH as a Robust Biomarker for Assessing Ovarian Aging in Individual Women. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2643-e2644.	1.8	6
622	Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohort. Rheumatology, 2021, 60, 1863-1870.	0.9	5
623	A bibliometric analysis of obstetrics and gynecology articles with highest relative citation ratios, 1980 to 2019. American Journal of Obstetrics & Synecology MFM, 2021, 3, 100293.	1.3	18
624	Polycystic ovary syndrome, amenorrhea and the diagnostic role of anti-M $\tilde{A}^{1}/4$ llerian hormone. Minerva Endocrinologica, 2021, 45, 376-380.	1.7	1
625	Use of AMH in the Differential Diagnosis of Anovulatory Disorders Including PCOS. Frontiers in Endocrinology, 2020, 11, 616766.	1.5	5
626	Characterization of Anti-MÃ $\frac{1}{4}$ llerian Hormone (AMH) Gene in Buffaloes and Goats. Frontiers in Veterinary Science, 2021, 8, 627094.	0.9	2
627	Reduced serum levels of anti-Mullerian hormone is a putative biomarker of early knee osteoarthritis in middle-aged females at menopausal transition. Scientific Reports, 2021, 11, 4931.	1.6	4
628	Fertility preservation in patients with BRCA mutations or Lynch syndrome. International Journal of Gynecological Cancer, 2021, 31, 332-338.	1.2	15
629	Anti-Mýllerian Hormone Related to Reproductive and Productive Longevity in Egyptian Buffaloes. Journal of Applied Veterinary Sciences, 2021, 6, 44-49.	0.0	0

#	Article	IF	CITATIONS
630	Anti-Mýllerian Hormone in Female Reproduction. Endocrine Reviews, 2021, 42, 753-782.	8.9	68
631	Predictive value of anti-Mýllerian hormone on pregnancy outcomes in in-vitro fertilization/intracytoplasmic single sperm injection patients at different ages. Archives of Gynecology and Obstetrics, 2021, 304, 1611-1620.	0.8	2
632	Could hormonal and follicular rearrangements explain timely menopause in unilaterally oophorectomized women?. Human Reproduction, 2021, 36, 1941-1947.	0.4	3
633	Fibroinflammatory Signatures Increase with Age in the Human Ovary and Follicular Fluid. International Journal of Molecular Sciences, 2021, 22, 4902.	1.8	17
635	Anti Mullerian Hormone A Putative Endocrine Marker in Prediction of Superovulation Response In Cattle. Black Sea Journal of Agriculture, 0, , .	0.1	0
636	Anti-Mullerian hormone (AMH) test information on Australian and New Zealand fertility clinic websites: a content analysis. BMJ Open, 2021, 11, e046927.	0.8	8
637	Body Composition and Serum Anti-Müllerian Hormone Levels in Euthyroid Caucasian Women With Hashimoto Thyroiditis. Frontiers in Endocrinology, 2021, 12, 657752.	1.5	5
638	Nomogram of age-specific anti-Müllerian hormone levels in healthy Egyptian females. PLoS ONE, 2021, 16, e0254858.	1.1	3
639	Anti-Mullerian Hormone Changes Following Laparoscopic Ovarian Cystectomy: A Prospective Comparative Study. International Journal of Women's Health, 2021, Volume 13, 691-698.	1.1	0
640	Duration, recency, and type of hormonal contraceptive use and antim $\tilde{A}^{1/4}$ llerian hormone levels. Fertility and Sterility, 2021, 116, 208-217.	0.5	19
641	Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis. Breast, 2021, 60, 155-162.	0.9	8
642	Clinical Utility of Anti-Mullerian Hormone in Pediatrics. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 309-323.	1.8	13
643	Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine. Endocrine Connections, 2021, 10, 1283-1290.	0.8	3
644	Comparison of the Automated Fluorescent Immunoassay System With Roche Elecsys and Beckman Coulter Access 2 Assays for Anti-Müllerian Hormone Measurement. Annals of Laboratory Medicine, 2022, 42, 47-53.	1.2	8
645	Fertility Preservation and Long-Term Monitoring of Gonadotoxicity in Girls, Adolescents and Young Adults Undergoing Cancer Treatment. Cancers, 2021, 13, 202.	1.7	18
646	BRCA1-Induced Ovarian Oncogenesis., 2008, 622, 89-97.		2
647	Current Understanding of Mullerian-Inhibiting Substance. , 2011, , 57-78.		1
648	Clinical Manifestation and Management of FXPOI. , 2016, , 199-224.		2

#	Article	IF	CITATIONS
649	Contraception Targets in Mammalian Ovarian Development. Handbook of Experimental Pharmacology, 2010, , 45-66.	0.9	5
650	Altered Expression of Anti-Mþllerian Hormone during the Early Stage of Bovine Persistent Ovarian Follicles. Journal of Comparative Pathology, 2018, 158, 22-31.	0.1	8
651	Anti-Mýllerian Hormone in the Diagnosis and Prediction of Premature Ovarian Insufficiency. Seminars in Reproductive Medicine, 2020, 38, 263-269.	0.5	9
652	Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecological Endocrinology, 2010, 26, 1-9.	0.7	25
653	Changes in antiâ€müllerian hormone levels as a biomarker for ovarian reserve after ultrasoundâ€guided highâ€intensity focused ultrasound treatment of adenomyosis and uterine fibroid. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 18-22.	1.1	30
654	Ovarian Reserve Assessment in Celiac Patients of Reproductive Age. Medical Science Monitor, 2018, 24, 1152-1157.	0.5	10
655	Effect of obesity on ovarian reserve parameters in mid-reproductive age women. F1000Research, 0, 1, 43.	0.8	3
656	A Validated Model of Serum Anti-Mý llerian Hormone from Conception to Menopause. PLoS ONE, 2011, 6, e22024.	1.1	360
657	Are Dieting and Dietary Inadequacy a Second Hit in the Association with Polycystic Ovary Syndrome Severity?. PLoS ONE, 2015, 10, e0142772.	1.1	12
658	Postponing Childbearing and Fertility Preservation in Young Professional Women. Southern Medical Journal, 2018, 111, 187-191.	0.3	12
659	The effects of both serum and follicular fluid anti-mullerian hormone on rate of the oocytes yield, fertilization & clinical pregnancy. İstanbul Kuzey Klinikleri, 2016, 3, 90-96.	0.1	6
660	The effect of laparoscopic hysterectomy with salpingectomy on ovarian function: the results of randomized clinical trial. Russian Journal of Human Reproduction, 2015, 21, 35.	0.1	2
661	The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women. International Journal of Fertility & Sterility, 2015, 8, 393-8.	0.2	35
662	Novel insights into the pathophysiology of chemotherapy-induced damage to the ovary. Panminerva Medica, 2019, 61, 68-75.	0.2	34
663	Analysis of anti mullerian hormone levels of female athletes and sedentary women. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2019, 178, .	0.0	1
664	Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF?. Journal of Human Reproductive Sciences, 2017, 10, 24-30.	0.4	27
665	Three-dimensional Ultrasound in the Fertility Clinic. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 2008, 2, 65-74.	0.1	2
666	Age-Specific Peripheral Anti-Mullerian Hormone (AMH) Concentration: A Candidate Endocrine Marker for Fertility Assessment in Cattle. International Journal of Livestock Research, 2019, , 1.	0.0	2

#	Article	IF	CITATIONS
667	Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-MÃ 1 /4llerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2014, 41, 86.	0.5	30
668	Clinical application of serum anti-M $\tilde{\text{A}}^{1}$ /4llerian hormone in women. Clinical and Experimental Reproductive Medicine, 2019, 46, 50-59.	0.5	43
669	Improvement in Serum Anti-Mýllerian Hormone Levels in Infertile Patients after Hyperbaric Oxygen (preliminary results). Jornal Brasileiro De Reproducao Assistida, 2015, 19, 87-70.	0.3	4
670	Are age and anti-MÃ $\frac{1}{4}$ llerian hormone good predictors of ovarian reserve and response in women undergoing IVF?. Jornal Brasileiro De Reproducao Assistida, 2018, 22, 215-220.	0.3	23
671	Which ovarian reserve marker relates to embryo quality on day 3 and blastocyst; age, AFC, AMH?. Jornal Brasileiro De Reproducao Assistida, 2020, 25, 109-114.	0.3	7
672	Anti-Mýllerian Hormone. , 2004, , 255-260.		0
673	Maternal Age and Oocyte Competence. , 2004, , 201-230.		0
674	Evidence-based Medicine and Clinical Algorithms. , 2005, , 23-52.		0
675	Endocrine aspects of reproductive aging in men and women. , 2005, , 17-27.		0
676	Premature Ovarian Failure. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 2007, 1, 64-79.	0.1	0
677	Poor Response to Controlled Ovarian Hyperstimulation. , 2009, , 37-80.		0
678	Regulation der Ovarfunktion. , 2009, , 91-115.		0
680	Female Reproductive Organ Testing. , 2009, , 399-425.		0
681	Natural and Surgical Menopause. , 2010, , 141-169.		0
682	Imagerie des Troubles de L'ovulation. , 2010, , 175-191.		0
683	Endokrinologische Diagnostik bei Kinderwunsch und regelmÃßigen Zyklen. , 2010, , 411-416.		0
684	Clinical efficacy of anti-Mullerian hormone inspection in supporting diagnosis for climacteric disorders. Open Journal of Internal Medicine, 2011, 01, 93-98.	0.1	0
685	Effects of bipolar electrocoagulation versus suture on ovarian reserve after laparoscopic excision of ovarian endometrioma. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2011, 27, 468-472.	0.0	0

#	Article	IF	CITATIONS
686	Current Understanding of Anti-Mýllerian Hormone. , 2011, , 19-33.		0
689	Évaluation du statut folliculaire ovarien. , 2011, , 199-208.		O
690	Antimýllerian hormone as a potential predictor for the late menopausal transition. Menopause, 2011, 18, 125-126.	0.8	0
691	La périménopause ou transition ménopausique. , 2012, , 243-256.		0
692	Gonaden (weiblich) Gonaden weiblich. , 2013, , 107-118.		0
693	Patient-Tailored Approaches to Ovarian Stimulation in ART. , 2013, , 137-153.		0
694	Die Patientin $\tilde{A}^{1}\!\!/\!\!\!\!\!/$ ber 40 mit Kinderwunsch. , 2013, , 397-406.		0
695	GYNECOLOGICAL ANTI-AGING. Juntendo Medical Journal, 2013, 59, 313-320.	0.1	0
696	From Primary Follicle to Ovulation. Gazi Medical Journal, 2013, 24, .	0.3	0
697	Physiology of Gametogenesis. , 2014, , 1-38.		0
698	3D Ultrasound for Follicle Monitoring in ART. , 2014, , 263-282.		0
699	ANTIMULLERIAN HORMONE SERUM CONCENTRATIONS IN NORMOOVULATORY AND ANOVULATORY WOMEN OF REPRODUCTIVE AGE. Journal of Sulaimani Medical College, 2013, 3, 117-124.	0.0	1
700	Age is the Best Marker to Predict Intracytoplasmic Sperm Injection Cycles Outcome. British Journal of Medicine and Medical Research, 2014, 4, 4076-4089.	0.2	1
701	Biomarkers of Menopausal. , 2014, , 1-10.		0
702	Determination of Ovarian Reserve with Anti-Mullerian Hormone in Patients with Polycystic Ovary Syndrome and Premenopausal Women. Journal of Academic Research in Medicine, 2014, 4, 62-68.	0.1	0
703	Gonaden (weiblich). , 2015, , 109-121.		O
704	Biomarkers of Menopause. Biomarkers in Disease, 2015, , 531-543.	0.0	0
705	Supplementation with DHEA in Poor Responder Patients. ISGE Series, 2015, , 119-127.	0.2	0

#	Article	IF	Citations
706	Fertility Management of Patients with Reduced Ovarian Reserve. , 0, s2, .		3
707	Progesterone Receptor Phosphorylation is Associated to Claudin 1 and 6 Expression and Pregnancy Success in ART-Treated Women. Endocrinology&Metabolism International Journal, 2015, 2, .	0.1	O
708	Evaluation of the impact of laparoscopic hysterectomy with fallopian tubectomy on ovarian function. Onkologiya Zhurnal Imeni P A Gertsena, 2016, 5, 12.	0.0	0
709	Decreased Serum Anti-Müllerian Hormone Level Is Associated with Vitamin D Deficiency in Healthy Japanese Women. Juntendo Medical Journal, 2016, 62, 153-159.	0.1	1
710	Genç ve Yaşlı Dişi Köpeklerde Foliküler Morfolojinin Farklılıkları ve Anti Müllerien Hormon ile İl Kafkas Universitesi Veteriner Fakultesi Dergisi, 2016, , .	iÅŸķisi. O.O	1
711	A Case Report on Two Spontaneous Pregnancies and Two Elevated Anti-Mý ullerian Hormone (AMH) of Subfertile Patients with Low AMH Level after Korean Medical Treatments. The Journal of Korean Obstetrics and Gynecology, 2016, 29, 135-143.	0.4	1
713	Korean Medical Treatment's Report about a Spontaneous Pregnancy with Low Anti-Müllerian Hormone (AMH) Level and Thin Endometrium Infertility after Anorectal Cancer Surgery. The Journal of Korean Obstetrics and Gynecology, 2016, 29, 68-77.	0.4	0
714	The relation between serum anti-Mullerian hormone levels and follicle count in polycystic ovary syndrome. The European Research Journal, 0, , .	0.1	0
715	Comparative Study between Measuring FSH, LH and E2 on Day Two and on Any Day of the Cycle. The Egyptian Journal of Hospital Medicine, 2017, 69, 1646-1654.	0.0	0
716	Gonaden (weiblich). , 2018, , 121-133.		0
717	Anti-mÃ $\frac{1}{4}$ llerian hormone as an fertility indicator in women of late reproductive age. Russian Journal of Human Reproduction, 2018, 24, 23.	0.1	0
718	FSH/LH Ratio as a Predictor of the IVF Outcome in Young Women. Open Journal of Obstetrics and Gynecology, 2018, 08, 817-825.	0.1	0
719	Study the Effect of Interleukin36 Gamma and AMH in Iraqi Women with PCOS. Mustansiriyah Journal of Science, 2018, 28, 151.	0.2	1
720	Neurop \tilde{A} ©ptide Y, anti-mullerian and reproductive hormones and their relationship with vasomotor symptoms in menopausal transition. Obstetrics & Gynecology International Journal, 2018, 9, .	0.0	0
721	La périménopause. , 2019, , 291-311.		0
722	COMPARATIVE STUDY OF OVARIAN RESERVE TESTS AND OVARIAN RESPONSE TO CONTROLLED OVARIAN STIMULATION IN IVF. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 1-8.	0.0	0
723	Anatomy and Physiology of Ovarian Follicle. , 2020, , 21-36.		0
724	Die Patientin $ ilde{A}^{1}\!\!/\!$	0.0	1

#	Article	IF	CITATIONS
725	Could art cycles have a detrimental effect on ovarian reserve? A retrospective case control study. Minerva Ginecologica, 2020, 72, 75-81.	0.8	0
726	Age-Related Value of Anti-Mullerian Hormone. Iraqi National Journal of Medicine, 0, , 111-116.	0.1	O
727	BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic review of the literature. Minerva Ginecologica, 2020, 72, 339-348.	0.8	2
728	Impact of Age on Hormonal Profiles of Sub-Fertile Women Attending Fertility Clinic in Umuahia, Abia State, South Eastern Nigeria. Open Journal of Internal Medicine, 2020, 10, 51-68.	0.1	3
730	Puberte prekokslu kızlarda anti-Müllerian hormon(AMH) düzeyinin folikül sayısı ve büyüklüÄ Turkish Journal of Clinics and Laboratory, 0, , .	ŸÃ¼ ile ili	ÅŸķisi.
731	Impact of Biological Factors Related to Maternal Aging: Risk of Childbirth with Down Syndrome., 0,,.		0
732	A Comparison of Fertility Rates in Women Undergoing IVF with a Tubal Factor with Surgery, Tubal Factor Infertility Without Surgery, and Unexplained Infertility., 2020, 5, 61-67.		0
733	The Gynecologist Has a Unique Role in Providing Oncofertility Care to Young Cancer Patients. US Obstetrics & Gynaecology, 2011, 6, 24-34.	1.0	13
734	The relationship between Anti-Mýllerian hormone and other reproductive parameters in normal women and in women with polycystic ovary syndrome. Journal of Medicine and Life, 2013, 6, 146-50.	0.4	5
735	Hormone changes associated with the menopausal transition. Minerva Ginecologica, 2009, 61, 483-9.	0.8	31
736	Genetic variants in anti-Mullerian hormone and anti-Mullerian hormone receptor genes and breast cancer risk in Caucasians and African Americans. International Journal of Molecular Epidemiology and Genetics, 2014, 5, 145-51.	0.4	1
737	Age-specific serum anti-mullerian hormone and follicle stimulating hormone concentrations in infertile Iranian women. International Journal of Fertility & Sterility, 2015, 9, 27-32.	0.2	9
738	Comparison of anti-Mullerian hormone level between uterine artery embolization and myomectomy in uterine fibroma. Journal of Medicine and Life, 2015, 8, 54-58.	0.4	2
739	Anti-Mý llerian Hormone Levels in Preeclampsia: A Systematic Review of the Literature. Journal of Family & Reproductive Health, 2017, 11, 179-184.	0.4	4
740	Comparative advantage of anti-Mullerian hormone over other ovarian reserve metric (basal hormonal) Tj ETQq0 2022, 9, 749-758.	0 0 rgBT /0 0.1	Overlock 10 T 0
741	A review of menopause nomenclature. Reproductive Health, 2022, 19, 29.	1.2	21
742	Association Between AMH Levels and Fertility/Reproductive Outcomes Among Women Undergoing IVF: A Retrospective Study. Journal of Reproduction and Infertility, 0, , .	1.0	0
743	Estrogen alpha receptor inactivation in two sisters: different phenotypic severities for the same pathogenic variant. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	3

#	Article	IF	CITATIONS
744	Correlation between serum AMH levels and cardiometabolic indices in PCOS women. Indian Journal of Endocrinology and Metabolism, 2021, 25, 545.	0.2	3
745	Anti-Mullerian Hormone Levels Increase After Bariatric Surgery in Obese Female Patients With and Without Polycystic Ovary Syndrome. Hormone and Metabolic Research, 2022, 54, 194-198.	0.7	7
746	Assessment of Telomere Length and Mitochondrial DNA Copy Number in Granulosa Cells as Predictors of Aneuploidy Rate in Young Patients. Journal of Clinical Medicine, 2022, 11, 1824.	1.0	6
747	A Correlation between Antral Follicle Count and Anti-MÃ $^{1}\!4$ llerian Hormone in Healthy Indian Women of Reproductive Age. Journal of SAFOG, 2022, 14, 1-5.	0.1	O
748	The putative roles of FSH and AMH in the regulation of oocyte developmental competence: from fertility prognosis to mechanisms underlying age-related subfertility. Human Reproduction Update, 2022, 28, 232-254.	5.2	19
750	Anti mullerian hormone and antral follicle count for prediction of ovarian reserve in female infertile patients. International Journal of Health Sciences, 0, , 1673-1683.	0.0	0
752	Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care. Journal of Clinical Medicine, 2022, 11, 2318.	1.0	18
753	Diagnostic and Treatment Considerations for Thyroid Cancer in Women of Reproductive Age and the Perinatal Period. Endocrinology and Metabolism Clinics of North America, 2022, 51, 403-416.	1.2	4
754	Anti-Müllerian hormone levels and breast cancer risk in the study of women's health across the nation. Cancer Causes and Control, 2022, 33, 1039-1046.	0.8	0
755	Does Maternal Vitamin D Level Affect the Ovarian Reserve of Female Newborn Infants?. Fetal and Pediatric Pathology, 0, , 1-9.	0.4	O
756	Correlation of serum anti-Mullerian hormone with hormonal and environmental parameters in Brazilian climacteric women. Scientific Reports, 2022, 12, .	1.6	1
757	Effect of Surgical Findings on Prediction of Postoperative Ovarian Reserve in Patients with Ovarian Endometrioma. International Journal of Women's Health, 0, Volume 14, 1127-1136.	1.1	1
758	Anti-Mullerian Hormone as a Marker of Ovarian Reserve and Function. Cureus, 2022, , .	0.2	3
759	Hormone concentrations of dominant follicles in the TALES randomized controlled trial comparing letrozole with tamoxifen. Journal of Assisted Reproduction and Genetics, 2022, 39, 2617-2624.	1.2	3
760	Kadın İnfertilitesinde AMH'nin Değerlendirilmesi ve Yorumlanması. Duzce Universitesi Tip Fakültesi Dergisi, 0, , .	0.3	0
761	An Oxidative Stress-Related Gene Signature in Granulosa Cells Is Associated with Ovarian Aging. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	1.9	7
762	AMH concentrations in infancy and mid-childhood predict ovarian activity in adolescence: a long-term longitudinal study of healthy girls. EClinicalMedicine, 2023, 55, 101742.	3.2	8
763	Age-related changes in Folliculogenesis and potential modifiers to improve fertility outcomes - A narrative review. Reproductive Biology and Endocrinology, 2022, 20, .	1.4	13

#	Article	IF	CITATIONS
764	Assisted Reproductive Technologies Across a Heterogeneous Patient Population. European Medical Journal Reproductive Health, 0 , , 2 - 9 .	1.0	0
765	HORMONAL STATUS OF PATIENTS WITH A PREDICTED WEAK RESPONSE OF THE OVARIES TO GONADOTROPIN STIMULATION. WiadomoÅ·ci Lekarskie, 2022, 75, 2374-2378.	0.1	1
766	Premature aging in childhood cancer survivors (Review). Oncology Letters, 2022, 25, .	0.8	3
767	Anti-MÃ $\frac{1}{4}$ llerian hormone for the diagnosis and prediction of menopause: a systematic review. Human Reproduction Update, 2023, 29, 327-346.	5.2	17
768	MAY THE SYSTEMIC IMMUNE-INFLAMMATION INDEX BE AN INDICATOR OF PREMATURE OVARIAN FAILURE?. Middle Black Sea Journal of Health Science, 0, , .	0.2	0
769	Systematic review of acupuncture to improve ovarian function in women with poor ovarian response. Frontiers in Endocrinology, 0, 14 , .	1.5	3
770	Assessment and quantification of ovarian reserve on the basis of machine learning models. Frontiers in Endocrinology, 0, 14 , .	1.5	3